

# Access and Reimbursement Guide

### A step-by-step guide to **coverage**, **claim submission and reimbursement** for patients who have been prescribed SUSVIMO

#### Indication

SUSVIMO (ranibizumab injection) is indicated for the treatment of patients with neovascular (wet) age-related macular degeneration (AMD) who have previously responded to at least 2 intravitreal injections of a vascular endothelial growth factor (VEGF) inhibitor medication.


#### **Important Safety Information**

#### WARNING: ENDOPHTHALMITIS

The SUSVIMO implant has been associated with a 3-fold higher rate of endophthalmitis than monthly intravitreal injections of ranibizumab. In clinical trials, 2.0% of patients receiving an implant experienced at least 1 episode of endophthalmitis.

Please see additional Important Safety Information in the full SUSVIMO Prescribing Information, including **BOXED WARNING**.





# Contact your Field Reimbursement Manager (FRM) for support.

### Genentech Is Here to Help Your Practice and Patients Throughout the SUSVIMO Treatment Process

This access and reimbursement guide is organized by the SUSVIMO treatment process. It provides additional resources available to your practice at each step.

#### **Before Surgery**

Enroll in Genentech patient support servic

Determine coverage for SUSVIMO .....

Apply for financial assistance, if necessar

Acquire SUSVIMO

#### **After Surgery**

Submit a claim for reimbursement .....

Navigate the denials and appeals process SUSVIMO reimbursement, if necessary...

Prepare for follow-ups and SUSVIMO refills

es	• •	• •	۰	• •	• •	•	• •	•	• •	• •	•	• •	•	• •	•		. 4
			• •	• •	•	• •	• •	•	• •	۰	• •	•	• •	• •		• •	. 6
у	• •	• •	•	0 0	• •	•	• •	•	• •	• •	• •	• •		• •	•		8
(		• •	• •	• •		• •	• (		• •	• •	• •		• •		• •	• •	10
			• •	• •	• •	•	• •	•	• •	۰	• •	•	• •	•	•	• •	12
for			• •	• •	•	• •	• •	•	• •	•	• •	•	• •	•	• •	• •	18
S	• •	• •	• •	•	• •	• •		• •	•	• •	• •		• •	• •	• •	•••	20



Coverage

Financial Assistance

Acquire SUSVIMO

Reimbursement

Navigate Denials and Appeals

### Get Your Patients Started With Genentech Patient **Support Services**

To enroll in coverage, reimbursement and financial assistance services, complete and submit the following 2 forms:



### **Prescriber Service Form**

Filled out by the health care provider and used to collect the patient's health insurance and treatment information



### **Patient Consent Form**

Completed by the patient and gives permission for Genentech to work with you and the patient's health insurance plan

### Finding and submitting the forms

Be sure to submit the prescriber and patient forms together for fast and efficient processing.

	Prescriber Service Form	Patient Consent Form
Where to find	SUSVIMO.com/support	Genentech-Access.com/ PatientConsent
How to submit	<ul> <li>Quick Enroll</li> <li>My Patient Solutions<sup>®</sup> for Health Care Practices</li> <li>Fax to (866) 724-9412</li> </ul>	<ul> <li>eSubmit</li> <li>My Patient Solutions for Health Care Practices</li> <li>Fax to (866) 480-7762</li> </ul>
		• Take a photo and text it to (650) 877-1111

# My Patient Solutions for Health Care Practices and My Patient Solutions for Sites of Care

### The flexibility to work with us when it's convenient for you

#### My Patient Solutions for Health Care Practices

My Patient Solutions for Health Care Practices helps you enroll patients in Genentech Ophthalmology Access Solutions and manage your service requests online.

- Features include:
- Message a Genentech Ophthalmology Access Solutions Specialist
- See which service requests require action
- Enroll and re-enroll patients in Genentech Ophthalmology Access Solutions or the **Genentech Patient Foundation**
- Send your patients a link to the paperless Patient Consent Form
- View Benefits Investigation Reports

### My Patient Solutions for Sites of Care

My Patient Solutions for Sites of Care is available for surgical centers that administer SUSVIMO. In this system, you can view and manage patients who have been referred to your facility for treatment.

Features include:

- Message a Genentech Ophthalmology Access Solutions Specialist
- View service requests
- View Benefits Investigation Reports
- Download the prior authorization form (if available)
- View co-pay assistance referrals

### Register for an account or log in at Genentech-Access.com/MPS.

Please see additional Important Safety Information in the full SUSVIMO Prescribing Information, including BOXED WARNING.

- View co-pay assistance referrals View Genentech Patient Foundation eligibility and coordinate shipments
  - · Customize, filter, sort and export your patient list
- Follow up on the status of prior authorizations or appeals - Download prior authorization form (if available)

- View Genentech Patient Foundation eligibility and track shipments
- Customize, filter, sort and export your patient list
- Log in once and navigate to both systems, if you are also registered for My Patient Solutions for Health Care Practices



Coverage

Financial Assistance

Acquire SUSVIMO

Reimbursement

Navigate Denials and Appeals

### Genentech Ophthalmology Access Solutions **Coverage and Reimbursement Support for SUSVIMO**

Genentech Ophthalmology Access Solutions works closely with practice managers, patient advocates and other health care professionals to identify and help resolve access and reimbursement issues for patients prescribed Genentech Ophthalmology treatments.

### We can help your patients and practice by providing:

- $\rightarrow$  Benefits investigations for drug and device
- → Benefits reverification support
- $\rightarrow$  Prior authorization resources
- $\rightarrow$  Information about authorized specialty pharmacies (SPs) and specialty distributors
- $\rightarrow$  Sample billing and coding information
- $\rightarrow$  Resources for denials and appeals
- $\rightarrow$  Referrals to financial assistance options

### Genentech Ophthalmology Access Solutions Can **Conduct a Benefits Investigation**

#### Learn about the patient's coverage through a benefits investigation

Genentech Ophthalmology Access Solutions can conduct a benefits investigation to help you determine if SUSVIMO is covered, if prior authorizations are required, which specialty pharmacy the health insurance plan prefers and if financial assistance is needed.

The benefits investigation will determine if the payer requires a specific surgical site. Once the surgical site is confirmed, the surgical coordinator will work with your patient to schedule the surgery.

A resource is available on **SUSVIMO.com/support** to help you and your patients understand the Benefits Investigation Report.

### SUSVIMO is covered under Medicare Fee-for-Service and Medicare Advantage.

However, some Medicare Advantage plans may require step edits before covering SUSVIMO. Please check the individual payer policies for more information.

The completion and submission of coverage- or reimbursement-related documentation are the responsibility of the patient and health care provider. Genentech makes no representation or quarantee concerning coverage or reimbursement for any service or item

6

### Considerations for Requesting a Prior Authorization for SUSVIMO

#### Tips for submitting prior authorizations

- Understand payer guidelines
- Submit all required supporting documents with the prior authorization request
- Keep complete records, including a copy of everything you send to the patient's health insurance plan
- Be sure to check the length of authorization with the payer, as this can vary

#### Commonly requested information for prior authorizations

Use the checklist below to help you navigate the approval process in the event that SUSVIMO requires a prior authorization. Your Field Reimbursement Manager (FRM) can help you understand specific payer policies.

#### Complete and submit the prior authorization form as required by the payer. Information required may include:

- Patient's name and date of birth
- · Patient's health insurance policy number Medical documentation to support the treatment decision
- Patient's diagnosis/ICD-10-CM code(s)
- Provider details, specialty, contact information and NPI number

#### If not part of the prior authorization form, consider including the following:

• Full Prescribing Information

#### Payers may require a letter of medical necessity written on the provider's letterhead. If so, include the following:

- Patient's current symptoms or condition
- Rationale for treatment with SUSVIMO • Previous treatment(s), duration and response or reason for discontinuation
- Patient-specific medical history related to the ICD-10-CM code(s)

#### If your patient's request for a prior authorization is not granted, your Field Reimbursement Manager (FRM) or Case Manager can work with you to determine your next steps.

ICD-10-CM=International Classification of Diseases, 10th Revision, Clinical Modification NDC=National Drug Code; NPI=National Provider Identifier.

Appeals cannot be completed or submitted by Genentech Ophthalmology Access Solutions on your behalf

SUSVIMO NDC

- Peer-reviewed journal articles
- Diagnostic test results





Coverage

Financial Assistance

Acquire SUSVIMO

Reimbursement

Navigate Denials and Appeals

### Financial Assistance Options for SUSVIMO

### Committed to helping patients, regardless of their ability to pay

If your patients have financial concerns related to SUSVIMO, we may be able to help.

### Help for eligible commercially insured patients

With the Genentech Ophthalmology Co-pay Program,\* patients pay as little as:

\$5 per drug co-pay,<sup>†</sup> up to \$15,000 per calendar year

**\$5** per drug administration co-pay,<sup>†‡</sup> up to \$1,000 per calendar year:

- Surgical co-pay for SUSVIMO procedure
- Refill co-pay for SUSVIMO

#### For more information or to get started:



8

Visit EyeOnCopay.com

Call (855) 218-5307, Monday through Friday, from 9 a.m.-8 p.m. ET

### Help for eligible commercially and publicly insured patients

If eligible commercially or publicly insured patients have difficulty paying for their co-pay, co-insurance or other out-of-pocket costs, Genentech Ophthalmology Access Solutions can refer them to an **independent co-pay assistance foundation**<sup>‡</sup> supporting their diagnosis.

#### For more information or to get started:

Visit SUSVIMO.com/support

Call (866) 724-9394, Monday through Friday, from 9 a.m.-8 p.m. ET

\*The Genentech Ophthalmology Product and Administrative Co-pay Program is valid ONLY for patients with commercial insurance who have a valid prescription for a Food and Drug Administration (FDA)-approved indication of a Genentech medication. Patients using Medicare, Medicaid or any other federal or state government program to pay for their medications are not eligible. To receive co-pay assistance for both drug cost and administration fees, patients must apply for and be enrolled in each type of program benefit, (i.e., drug cost and administration fees). Under the programs, the patient will pay a co-pay for drug costs and a co-pay for administration costs. After reaching the maximum per treatment or annual limit, the patient will be responsible for all remaining out-of-pocket expenses. The amount of the program's benefits cannot exceed the patient's out-of-pocket expenses for the cost of the drug or administration fees associated with SUSVIMO.

All participants are responsible for reporting the receipt of all program benefits as required by any insurer or by law. The programs are only valid in the United States and U.S. Territories. These programs are void where prohibited by law. The product co-pay program shall follow state restrictions in relation to AB-rated generic equivalents (e.g., MA, CA) where applicable. The administration co-pay program is not valid for Massachusetts or Rhode Island residents. The patient, guardian, prescriber, hospital and any other person using or administering the programs agree not to seek reimbursement for all or any part of the benefit received by the patient through the offer of this program. Genentech reserves the right to rescind, revoke or amend the program without notice at any time. Additional Terms and Conditions apply. Please visit EyeOnCopay.com for the full list of Terms and Conditions.

<sup>1</sup>The final amount owed by patients may be as little as \$5, but may vary depending on the patient's health insurance plan. Eligible commercially insured patients who are prescribed SUSVIMO for an FDA-approved use can receive up to \$15,000 in assistance per calendar year for drug costs and/or up to \$1,000 in administration assistance per calendar year for SUSVIMO surgical procedure and refill costs. The program benefit does not reset if a patient switches from one Genentech Ophthalmology treatment to another. It does not help with facility fees. See terms and conditions for each program. Program limits apply.

<sup>‡</sup>Independent co-pay assistance foundations have their own rules for eligibility. Genentech has no involvement or influence in independent foundation decision-making or eligibility criteria and does not know if a foundation will be able to help your patient. We can only refer your patient to a foundation that supports their disease state. Genentech does not endorse or show preference for any particular foundation. The foundations to which we refer your patient may not be the only ones that might be able to help.

### Help for uninsured or underinsured patients

If patients don't have health insurance coverage or have financial concerns and meet eligibility criteria, they may be able to get free medicine from the **Genentech Patient Foundation**.

### Genentech Patient Foundation Eligibility Criteria<sup>§</sup>

Uninsured patients with incomes under \$150,000



Insured patients without coverage for a Genentech medicine with incomes under \$150,000

Insured patients with coverage for a Genentech medicine<sup>II</sup>

OR)

- With unaffordable out-of-pocket costs
- With household size and income within the guidelines listed to the right

To enroll eligible patients directly in the Genentech Patient Foundation, have your patients complete the Patient Consent Form and you will complete the Prescriber Foundation Form, which can be found at GenentechPatientFoundation.com.

#### For more information or to get started:



Call (888) 941-3331, Monday through Friday, from 9 a.m.-8 p.m. ET

For all patient types, add \$25,000 for each extra person in households larger than 4 people. "We encourage insured patients to pursue other financial assistance options prior to applying for help from the Genentech Patient Foundation, if possible.

Genentech reserves the right to modify or discontinue the program at any time and to verify the accuracy of information submitted

lousehold size	Annual income
名 1	Less than \$75,000
<u> </u>	Less than \$100,000
<u> </u>	Less than \$125,000
<u> </u>	Less than \$150,000





# Enrollment

Coverage

Acquire SUSVIMO

Reimbursement

Navigate Denials and Appeals

## Acquiring SUSVIMO

SUSVIMO is implanted in the eye during a one-time, outpatient procedure performed in the operating room.<sup>1</sup> The Refill-Exchange Procedure is designed to be performed in an office-based setting at the 6-month interval.<sup>2</sup>

SUSVIMO Implantation Kit will be ordered by the ambulatory surgical center or hospital outpatient department for the Initial Fill and Implant Procedure, and the SUSVIMO Refill-Exchange Kit will be ordered by the retina specialist office for Refill-Exchange Procedures.


### How SUSVIMO is supplied

#### The SUSVIMO Implantation Kit contains 2 components:

SUSVIMO Injection and Initial Fill Needle Carton

Susvimo <sup>™</sup> (ranibizumab injection)	See instructions for use included with the Susvimo ocular implant with insertion tool assembly	
100 mg/mL		Salary .
Val contains 10 mg/0.1 mL ranibizumab For use with Susvimo ocular implant Dispense the enclosed Medication Guide to each pat Carton contents: - One Suvimo single-Gose vial - One Suvimo initial fill needle	ert. Bowy Genentsch	

SUSVIMO Ocular Implant With Insertion **Tool Assembly Carton** 



NDC: 50242-078-55

Contact your authorized distributor for the device ordering number.

#### The SUSVIMO Refill-Exchange Kit contains 2 components:

SUSVIMO Injection Carton



NDC: 50242-078-12

SUSVIMO Refill Needle Carton



Contact your authorized distributor for the device ordering number.

For additional information on ordering, please see the SUSVIMO Ordering Guide found on
SUSVIMO.com/support or reach out to your Surgical Device Specialist. Ancillary tools
(e.g., Explant Tool, Refill Needles) may be ordered through the Genentech Ophthalmology
Support Line: <b>(833) EYE-GENE</b> /(833) 393-4363, prompt 2.

References: 1. SUSVIMO initial fill and implant procedure instructions for use. Genentech, Inc. 2021. 2. SUSVIMO Procedure Guide Genentech, Inc. 2021.

10 Please see additional Important Safety Information in the full SUSVIMO Prescribing Information, including **BOXED WARNING**.

## **Distributors for SUSVIMO**


	Phone
Besse Medical	(800) 543-2111
Cardinal Health	(866)677-4844
CuraScript SD	(877) 599-7748
McKesson Specialty Health	(855) 477-9800
Metro Medical	(800)768-2002

### **Tips for working with distributors**



For the latest list of authorized specialty distributors, visit Genentech-Access.com/SUSVIMO.

Genentech does not influence or advocate the use of any one specialty distributor. We make no representation or guarantee of service or coverage of any item









Coverage

Financial Assistance

Acquire SUSVIMO

Reimbursement

Navigate Denials and Appeals

Follow-ups

11

### Sample Coding for SUSVIMO

This coding information may assist you as you submit claims for reimbursement for SUSVIMO.

#### ICD-10-CM diagnosis codes

Code	Description
H35.3211	Exudative age-related macular degeneration, right eye, with active choroidal neovascularization
H35.3212	Exudative age-related macular degeneration, right eye, with inactive choroidal neovascularization with involuted or regressed neovascularization
H35.3221	Exudative age-related macular degeneration, left eye, with active choroidal neovascularization
H35.3222	Exudative age-related macular degeneration, left eye, with inactive choroidal neovascularization with involuted or regressed neovascularization
H35.3231	Exudative age-related macular degeneration, bilateral, with active choroidal neovascularization
H35.3232	Exudative age-related macular degeneration, bilateral, with inactive choroidal neovascularization with involuted or regressed neovascularization
H35.3291	Exudative age-related macular degeneration, unspecified eye, with active choroidal neovascularization
H35.3292	Exudative age-related macular degeneration, unspecified eye, with inactive choroidal neovascularization with involuted or regressed neovascularization

ICD-10-CM=International Classification of Diseases, 10th Revision, Clinical Modification.

These codes are not all-inclusive; appropriate codes can vary by patient, setting of care and payer. Correct coding is the responsibility of the provider submitting the claim for the item or service. Please check with the payer to verify codes and special billing requirements. Genentech does not make any representation or guarantee concerning reimbursement or coverage for any service or item.

Many payers will not accept unspecified codes. If you use an unspecified code, please check with your payer.

### Drug and drug administration codes

Claims to submit vary by site of care and procedure.

Biller	Code
--------	------

#### **Initial Fill and Implant Procedure**

*		10-digit	50242-078-55			
Inter	NDC	11-digit	50242-0078-55			
Surgical Centers*	HCPCS		J2779†			
Surgi	Facility f	ee: CPT	67027			
Retina Surgeon	Profession services		67027			

#### **Refill-Exchange Procedure**

ġ	NDC	10-digit	50242-078-12			
a Office	NDC	11-digit	50242-0078-12			
Retin	HCPCS		J2779†			
Spec	Profession services		67028			

#### SUSVIMO billing direction

#### Initial fill and implant procedure

- Bill 20 units with J2779 for the 2-mg administered dose of SUSVIMO
- On a separate line, bill 80 units with J2779 and the JW modifier for discarded drug

#### **Refill-exchange procedure**

• Bill 100 units with J2779 without the JW modifier<sup>‡</sup>

CPT=Current Procedural Terminology; HCPCS=Healthcare Common Procedure Coding System; NDC=National Drug Code. \*For Medicare, hospital outpatient departments should also report the cost of the implant using HCPCS code C1889 (implantable/insertable device, not otherwise classified).

 $^{\dagger}J2779$  is effective for services provided on or after July 1, 2022.

<sup>‡</sup>The guidance being provided, that use of the JW modifier is not required for the refill procedure, is based on our understanding of our product and is subject to change pending legislative and/or regulatory developments.

Providers should specify the total milligram amount of SUSVIMO administered and discarded (as appropriate based on procedure) within the clinical documentation for the patient.

#### Description

SUSVIMO (100 mg/mL) single-dose vial and initial fill needle (34-gauge needle with a 5-µm integrated filter)

Injection, ranibizumab, via intravitreal implant (susvimo), 0.1 mg

Implantation of intravitreal drug delivery system (e.g., ganciclovir implant), includes concomitant removal of vitreous

Implantation of intravitreal drug delivery system (e.g., ganciclovir implant), includes concomitant removal of vitreous

SUSVIMO (100 mg/mL) single-dose vial

Injection, ranibizumab, via intravitreal implant (susvimo), 0.1 mg

Intravitreal injection of a pharmacologic agent (separate procedure)

e of SUSVIMO modifier for discarded drug





Enrollment

Navigate Denials and Appeals

Follow-ups

-13

### Sample Claim Form: CMS-1500

#### Typically used for initial fill and implant procedures and refill-exchange procedures in physician office and ambulatory surgical center (ASC) settings

The CMS-1500 claim form is used to bill for services provided in the physician office and ASC setting. The CMS-1500 claim form is shown here as an example. Check with individual payers for specific documentation requirements.

Insert appropriate ICD-10-CM diagnosis code(s).

Report NDC information in the shaded area in the following order: N4 qualifier, 11-digit NDC followed by 1 space, unit of measurement qualifier and metric quantity.

Enter the appropriate place of service: 24 for ASC or 11 for retina specialist office.

Document use of drug with the appropriate HCPCS code on 1 line and the appropriate CPT administration code(s) on a separate line.

- For the initial fill and implant procedure: Bill 20 units with J2779 for the 2-mg administered dose of SUSVIMO. On a separate line, bill 80 units with J2779 and the JW modifier for discarded drug
- For the refill-exchange procedure: Bill 100 units with J2779 without the JW modifier\*

PEROVED BY MATIONAL ON FORMALIA MICONMITTEE (NUCL	M						
T PCA	cyce iz						POATT
				La INSUPERVATIO N	UNANE		(Les Program in June 1)
Filddewait/ Machangel (105.50517 ) p 2. PATRIXTIS NAME II AN KANA, PHY PATRI, Vidde II Lett	Menderide, nde,	× [] 19	· • • • • •				
THE RECEIPTION OF A DECK PRESENCE WORK OF LAND	S PAT UNI	S BRILDATE	261	<ul> <li>USUBED'S HAVE</li> </ul>	cuell North	e, Pesthame, A	dissile in seg
MARKING ADDRESS (Ab. Soan)	5 PATIENT	HELANORSHEP IN	UNSURED	7 PISURED'S ADDR	SS (Mg., 1	Street.	
ux.		Soon to Chief	00-0-				
	STATE & RESERVE	ED FOR MUSIC 1/48		d fv			STATE,
SPE GOVE TEEEPHONE Invelues Avea Cos	a)			28 0000		TELEPHONIC	Onchase even Carley
( )						(	)
OTHER LINGUISTIC AND LAND NAME, THIS have Note the	41 10 /\$ PA*16	End & Dideated above	device to	11 WELVED S POLK	17 GROUP	OR RECAINUS	WEER
OTHER INSURED'S POLICY OR GROUP NUMBER	+ SHPLDP	MENT (Control of )	Page-100497	· NSUPER STRATE	SF Ren (je		186 m
		□ ** □	] 🗝	QU CD	44	4[	<u> </u>
RESERVED FOR NUCC USC	e auto ad		Puict (Seen	> OTHER OLANS D /	Designation	oy we be	
INCREMENTED FOR MUCCIUSE	e Ofrite A	CENTRAL C	H0	C PISURANCE PLAN	NAME OF	PROCEAU PA	UK
		VII5	] 🛛 🕹				
INSURANCE PLAN YANF DR PROGRAM SAME	106, 01,914	10s. CLARK CODES (Designed b) NUCC)			I IS THERE ANOTHER HEALTH DESIGN FRANK		
APAD DACK OF SOON SERVICE ONLY	DI STRUG & Decoration	Teatherstein		VES AO Greek complete remain 2 As and both 10 ANSWEED S OF A UTHORIZED MEMORY'S SIGN ATUNE Reconcilian			
READ BACK OF FORM DEFORE COM ACTENTS OF ALTHORIZED PERSONS S STATUTE ALTHOR to precise the Call T 14 to Internal Control of Sector March before	of a the viewe of any G affection yould be to	men cal or other inte The party who accept	maaan naniksaay Ia wagemen	payment described	Iboner/s to	t ine unders gre	ado A TUNE Peceborga ed physician or guggles for
5%ee0		ane		5×64E0			
<ul> <li>BATE DE CORRENT SURESS, MUCHY, MIDGMANGY (LM DO DO D</li></ul>	n) is other parts	44 00		IS DATES PATIENT	WALLS I	WORK IN CO	NAT DOCLPATION
CON. 1. HAND OF REFERENCE PERMITER OR OTHER SOLVED.	17a			FROM		10	
	170 1021		ENDERING FATIO	, and W	té	WW 60 TY	
P. ADDITIONAL CLARING OF MALLOR (Designated by NUCC)				20 OUTS-DE LAST	-	2.04	44065
DREPOSIS OF HATURE OF BUILTSSICK, INJUNY, PASH AV	l				NG		
		(See) ICD Vd.		COXE	1	DRAWE MP	r. 60.
6	¢ i			20 PROLATINGS	AT40 S JRI	WREA	
	8.1	4.1					
From to Public	PROCEDURES, SERV (Explain Virusual Cri	MOD FIER	04640545		Divis Divis Unit	It I	newcomes
- co ri via bo ri sparte (vio e	Plakenes	NUDSHER	PONIER	S CHANGES	0474	no dell	PROVICER (0.1
						MPI	
		1 1 1				NPI	
					24G	NPI	
24A 24B	2411					A	
24A 24B	24D						
24A 24B	240	1 1 1	1			NPI	
24A 24B	240					NPI p.Pi	
24A 24B	240					- p. Pa	
		27. 40780			36	- p.Pi	The line of local difference
		27 <u>4555</u>		78 1014, CHARSE		- p. Pa	20 Have feer full too U
		- ses	Ma		\$		20 Yeard fee 10, 50 U
FT2CRA: Tax D 11,0163 550 EM. SC PART	ENT'S ACCOUNT NO	- ses	Ma	\$	\$		00 (hod for in 100 0 ;

Include the number of units used for each line item.

ASC=ambulatory surgical center; HOPD=hospital outpatient department

\*The guidance being provided, that use of the JW modifier is not required for the refill procedure, is based on our understanding of our product and is subject to change pending legislative and/or regulatory developments.


Providers should specify the total milligram amount of SUSVIMO administered and discarded (as appropriate based on procedure) within the clinical documentation for the patient

Correct coding is the responsibility of the provider submitting the claim for the item or service. Please check with the payer to verify codes and special billing requirements. Genentech does not make any representation or guarantee concerning reimbursement or coverage for any service or item


# Sample Claim Form: CMS-1450

### Typically used for initial fill and implant procedures in hospital outpatient department (HOPD) and ASC

The CMS-1450 (also known as the UB-04) claim form is used to bill for services provided in the HOPD and ASC. The CMS-1450 claim form is shown here as an example. Check with individual payers for specific documentation requirements.



route of administration and NDC.



Coverage

Financial Assistance

Acquire SUSVIMO

Reimbursement

Navigate Denials and Appeals

Follow-ups



SUSVIMO ranibizumab injection For Ocular

#### SUBMIT A CLAIM FOR REIMBURSEMENT (CONT)

### Reimbursement Considerations by Payer Type



### Medicare<sup>1</sup>

For products that will be reimbursed under Medicare Part B, like SUSVIMO, Medicare generally reimburses these products based on a percentage of the average sales price (ASP). CMS calculates ASP on a guarterly basis. The percentage varies based on the treatment setting. SUSVIMO reimbursement for physician offices, ASCs and HOPDs (340B Program and non-340B) will be based on ASP + 6%.

#### For the Retina Specialist<sup>2</sup>

• Medicare Part B provides reimbursement at a rate of the ASP plus a 6% add-on fee (ASP + 6%)

#### For the Ambulatory Surgical Center (ASC)/ Hospital Outpatient Department (HOPD)<sup>2</sup>

Effective April 1, 2022, SUSVIMO gualifies for pass-through status\* through the Outpatient Prospective Payment System (OPPS) when administered in the HOPD or ASC setting

- SUSVIMO will continue to have pass-through status through March 31, 2025, facilitating separate payment in the HOPD. When pass-through status expires on March 31, 2025, 340B Program HOPDs will be reimbursed at ASP - 22.5%
- Per CMS policy, SUSVIMO will always be separately paid in the ASC even after pass-through status ends
- The ASC/HOPD will be paid 80% of the calculated price and the patient will be billed 20% of the calculated price, after the deductible is met
- These drugs and biologicals are not eligible for outlier payment
- Drugs and biologicals that are acquired under the 340B Program will continue to be paid at ASP - 22.5%, Wholesale Acquisition Cost (WAC) - 22.5% or 69.46% of Average Wholesale Price (AWP), as applicable

Note: Please visit CMS.gov to learn about current reimbursement rates.

Due to sequestration, Medicare FFS claims incur a 2% reduction in payment, resulting in an effective rate of WAC + 1.35% and ASP + 4.3% reimbursement for separate payable drugs under Part B.<sup>3</sup>

\*Pass-through status is intended for the use of newly approved or costly drugs. Medicare pays hospitals for the procedure and makes an additional pass-through payment for the drug, for the first 2 to 3 years. After pass-through status expires, Medicare pays for the drug as part of a single payment for the procedure.4

### Reimbursement Considerations by Payer Type (cont)



### Medicaid<sup>4</sup>


Medicaid reimbursement varies by state. Often, payment methodologies follow Medicare and are based on a percentage of ASP, WAC, AWP, invoice pricing or another means. However, they could be lower or higher than Medicare in any particular state.



### **Commercial payers**

Commercial payer reimbursement varies and is based on the contracted rate with the provider. Review your contracts to understand your specific reimbursement rates.

The following list provides some important information you may wish to consider regarding your commercial payer contracts:



- Determine the contract term, renewal date and termination time frame
- Document contact information for the payer and your site of care's designated payer relations representative

References: 1. MedPAC. Improving Medicare's payment for Part B drugs: Requiring pharmaceutical manufacturer reporting of sales price data. Published June 14, 2019. Accessed April 22, 2022. https://www.medpac.gov/improving-medicares-payment-for-part-b-drugsrequiring-pharmaceutical-manufacturer-reporting-of-sales-price-data/ 2. Medicare program: changes to hospital outpatient prospective payment and ambulatory surgical center payment systems and quality reporting programs. Fed Regist. 2018;83(225):58818-59179. Accessed April 22, 2022. https://www.govinfo.gov/content/pkg/FR-2018-11-21/pdf/2018-24243.pdf 3. U.S. Government Accountability Office. Medicare Part B: payments and use for selected new, high-cost drugs. Published March 1, 2021. Accessed April 29, 2022. https://www.gao.gov/ products/gao-21-252 4. Centers for Medicare & Medicaid Services. 2% payment adjustment (sequestration) changes. Published December 16, 2021. Accessed May 25, 2022. https://www.cms.gov/outreach-and-educationout reachffsprovpartprogprovider-partnership-email-archive/2021-12-16-mlnc 5. Medicaid covered outpatient prescription drug reimbursement information by state: guarter ending September 2021. Medicaid website. Accessed April 22, 2022. https://www.medicaid.gov/medicaid/ prescription-drugs/state-prescription-drug-resources/medicaid-covered-outpatientprescription-drug-reimbursement-information-state/index.htm ranibizumab injection 🖁





Coverage

Financial Assistance

Acquire SUSVIMO

Reimbursement

Navigate Denials and Appeals

#### GATE THE DENIALS AND APPEALS PROCESS FOR SUSVIMO REIMBUR

#### APPEAL PROCESS

20

### Understanding the Reason for a Denial Is Essential

If a plan issues a denial, ensure you understand the reason for the denial.

### **Overview of denial and appeal processes**

- Understand why coverage was denied.
- Understand the payer's specific process or requirements, and that individual payers may have their own forms or documentation requirements.
- Review provided sample appeal letters and cross-reference the list of commonly requested documents on this page.
- Submit your appeal to the health insurance plan.

Some common reasons for denials include, but are not limited to, the following\*:

- New drug not yet reviewed by payer and considered nonformulary
- Lack of prior authorization or precertification
- Missing information or data error in the coverage request
- Insurance information has changed or coverage has lapsed
- Failure to follow a step-edit

## If a request for coverage of SUSVIMO is denied, you may request an appeal

#### Each health plan has its own appeals process.

The plan will advise you of the number of internal appeals that can be filed, instructions for the appeal, deadlines and the forms to be completed.

#### If you are not satisfied with the plan's final response, most plans allow for an external appeal.

An external appeal is a review of the health plan's decision by an independent third party that can overturn the plan's decision. Your health plan will give you guidance on what specific steps to follow in the denial letter.

Your Field Reimbursement Manager (FRM) or Genentech **Ophthalmology Access Solutions Specialist** has local payer coverage expertise and can help you determine specific appeal requirements for your patient.

\*In some cases it may be necessary to submit a formulary exception request to the payer Appeals cannot be completed or submitted by Genentech Ophthalmology Access Solutions on your behalf.

### SUSVIMO Appeals Request Process and Checklist

### Common considerations for submitting an appeal



- Verify the accuracy of all documentation:
- Appeal letter
- Denial documentation
- Medical documentation
- Other supporting documentation
- Has coverage for SUSVIMO been established for the patient's condition/diagnosis? • Did the prior authorization include all information as required by the payer?
- Was the health insurance information correct?
- Did the patient's health insurance change or coverage lapse?

#### Initiate the appeals process

For commercial payers, there are typically 3 levels of appeals for a health plan decision:

### **First-level appeal**

Contact payer to request a reconsideration of the denial. This may include a "peer-to-peer" discussion with the medical reviewer.

### Second-level appeal

At this step, the appeal is typically reviewed by a medical director of the plan to determine if the request should be accepted within the coverage guidelines.

### Independent external review

If attempts to appeal a coverage decision have not been successful, an external review can be conducted by an independent third party to make a binding decision.

Visit **CMS.gov** for additional information on the appeal process and various levels of appeals for Medicare.

Sample appeal letters are available at SUSVIMO.com/support.



Coverage

Financial Assistance

Acquire SUSVIMO

Reimbursement

Navigate Denials and Appeals

#### EPARE FOR FOLLOW-UPS AND SUSVIMO REF

SUSVIMO refills will be scheduled approximately every 6 months in the retina specialist's office, or as determined by the retina specialist.

#### **Benefits reverification support**

Genentech Ophthalmology Access Solutions can help you request reverification for your patients.

### **Considerations for reverifications include:**

Identify which patients require reverifications



Document any prior authorization numbers and expiration dates

Gather required forms and documents

Work within the required timing to avoid treatment delays

Proactively performing reverifications can help avoid potential gaps in your patients' treatment with SUSVIMO.

#### **Replacing spoiled medicine**

The Genentech Spoilage Replacement Program provides for replacement of infused, injected and self-administered products, which are prescribed and prepared for a labeled indication, yet not administered due to unforeseen patient clinical circumstances, subject to certain limitations and conditions set forth by Genentech. The purpose of the program is to support our commitment to protecting patient safety by preventing the use of spoiled, damaged or contaminated products.

Please visit **gene.com/customerservice** and select returns or call (833) EYE-GENE/(833) 393-4363 and press 2 to submit a request for replacement of spoiled product or to obtain additional information about the Program.

### Genentech Patient Support Services for SUSVIMO

#### Genentech is here to help your patients begin and continue to access SUSVIMO

We believe every person should get the SUSVIMO they need, and we offer programs to help make this happen.



### **Genentech Ophthalmology Access Solutions**

For people who need help understanding health insurance coverage and costs related to SUSVIMO



### **Genentech Patient Foundation**

For people who do not have health insurance coverage or who have concerns about the cost of SUSVIMO and meet certain eligibility criteria



### **Affordability Options**

- For people who have health insurance and can't afford SUSVIMO:
- Genentech Ophthalmology Co-pay Program
- Referrals to independent co-pay assistance foundations

Not sure what you need? Visit SUSVIMO.com/support to learn more. Or call (833) EYE-GENE/(833) 393-4363 Monday-Friday, 9 a.m.-8 p.m. ET

The completion and submission of coverage- or reimbursement-related documentation are the responsibility of the patient and health care provider. Genentech makes no representation or guarantee concerning coverage or reimbursement for any service or



Coverage

Financial Assistance

Acquire SUSVIMO

Reimbursement

Navigate Denials and Appeals

#### Indication

SUSVIMO (ranibizumab injection) is indicated for the treatment of patients with neovascular (wet) age-related macular degeneration (AMD) who have previously responded to at least 2 intravitreal injections of a vascular endothelial growth factor (VEGF) inhibitor medication.

#### **Important Safety Information**

#### WARNING: ENDOPHTHALMITIS

The SUSVIMO implant has been associated with a 3-fold higher rate of endophthalmitis than monthly intravitreal injections of ranibizumab. In clinical trials, 2.0% of patients receiving an implant experienced at least 1 episode of endophthalmitis.

#### Contraindications

- Ocular or periocular infections
- Active intraocular inflammation
- Hypersensitivity

#### **Warnings and Precautions**

- The SUSVIMO implant and/or implant-related procedures have been associated with endophthalmitis, rhegmatogenous retinal detachment, implant dislocation, septum dislodgement, vitreous hemorrhage, conjunctival retraction, conjunctival erosion, and conjunctival bleb. Patients should be instructed to report signs or symptoms that could be associated with these events without delay. Additional surgical and/or medical management may be required
- Vitreous hemorrhage: Temporarily discontinue antithrombotic medication prior to the implant insertion procedure to reduce the risk of vitreous hemorrhage. Vitrectomy may be needed
- Postoperative decrease in visual acuity: A decrease in visual acuity usually occurs over the first 2 postoperative months

#### **Adverse Reactions**

The most common adverse reactions were conjunctival hemorrhage (72%), conjunctival hyperemia (26%), iritis (23%), and eye pain (10%).

You may report side effects to the FDA at (800) FDA-1088 or www.fda.gov/medwatch. You may also report side effects to Genentech at (888) 835-2555.

### Notes

Coverage

Financial Assistance

Acquire SUSVIMO

Reimbursement

Navigate Denials and Appeals




## Choose How You Want to Connect With Us

- Visit SUSVIMO.com/support
- Call our Specialists at (833) EYE-GENE/(833) 393-4363
- Get support from a Field Reimbursement Manager (FRM)
- Manage your patients online with My Patient Solutions<sup>®</sup> for Health Care Practices



Please see additional Important Safety Information in the full SUSVIMO Prescribing Information, including **BOXED WARNING**.

SUSVIMO<sup>™</sup> and its logo are trademarks and My Patient Solutions<sup>®</sup> is a registered trademark of Genentech, Inc.

©2022 Genentech USA, Inc. So. San Francisco, CA All rights reserved. M-US-00012069(v4.0) 07/22 Printed in USA



#### HIGHLIGHTS OF PRESCRIBING INFORMATION

These highlights do not include all the information needed to use SUSVIMO safely and effectively. See full prescribing information for SUSVIMO.

SUSVIMO<sup>®</sup> (ranibizumab injection) for intravitreal use via SUSVIMO ocular implant Initial U.S. Approval: 2006

#### WARNING: ENDOPHTHALMITIS

See full prescribing information for complete boxed warning.

The SUSVIMO implant has been associated with an up to 3-fold higher rate of endophthalmitis than monthly intravitreal injections of ranibizumab.

RECENT MAJOR CHANGES	
Indications and Usage, Diabetic Macular Edema (DME) (1.2)	2/2025
Dosage and Administration (2.2)	2/2025
Warnings and Precautions (5.1, 5.5, 5.6, 5.7, 5.8)	2/2025

- Neovascular (wet) Age-related Macular Degeneration (AMD) who have previously responded to at least two intravitreal injections of a VEGF inhibitor (1.1).
- Diabetic Macular Edema (DME) who have previously responded to at least two intravitreal injections of a VEGF inhibitor (1.2).

-----DOSAGE AND ADMINISTRATION-----

- For intravitreal use via SUSVIMO ocular implant. (2.1)
- The recommended dose of SUSVIMO (ranibizumab injection) is 2 mg (0.02 mL of 100 mg/mL solution) continuously delivered via the SUSVIMO implant with refills every 24 weeks (approximately 6 months) for AMD and DME. (2.2)
- Supplemental treatment with 0.5 mg intravitreal ranibizumab injection may be administered in the affected eye if clinically necessary. (2.3)

#### FULL PRESCRIBING INFORMATION: CONTENTS\*

#### WARNING: ENDOPHTHALMITIS

- 1 INDICATIONS AND USAGE
  - 1.1 Neovascular (Wet) Age-Related Macular Degeneration (AMD)
  - 1.2 Diabetic Macular Edema (DME)
- 2 DOSAGE AND ADMINISTRATION
  - 2.1 General Information
    - 2.2 Neovascular (Wet) Age-Related Macular Degeneration (AMD) and Diabetic Macular Edema (DME)
    - 2.3 Supplemental Treatment with Intravitreal Ranibizumab Injection
    - 2.4 Ocular Implant Initial Fill
    - 2.5 Ocular Implant Insertion
    - 2.6 Ocular Implant Removal
    - 2.7 Ocular Implant Refill-Exchange Procedure
  - 2.8 Delayed or Missed doses
  - 2.9 Dosage (Refill-Exchange) Modifications for Adverse Reactions
  - DOSAGE FORMS AND STRENGTHS
- CONTRAINDICATIONS

3

- 4.1 Ocular or Periocular Infections
- 4.2 Active Intraocular Inflammation
- 4.3 Hypersensitivity

#### 5 WARNINGS AND PRECAUTIONS

- 5.1 Endophthalmitis
  - 5.2 Rhegmatogenous Retinal Detachment
  - 5.3 Implant Dislocation
  - 5.4 Septum Dislodgement
  - 5.5 Vitreous Hemorrhage
  - 5.6 Conjunctival Erosion or Retraction
  - 5.7 Conjunctival Bleb

 Perform the initial implantation, refill-exchange, and implant removal (if necessary) procedures under strict aseptic conditions. (2.4, 2.5, 2.6, 2.7)

#### 

#### -----CONTRAINDICATIONS------

- Ocular or periocular infections (4.1)
- Active intraocular inflammation (4.2)
- Hypersensitivity (4.3)

#### -----WARNINGS AND PRECAUTIONS------

- The SUSVIMO implant and/or implant-related procedures have been associated with endophthalmitis, rhegmatogenous retinal detachment, implant dislocation, septum dislodgement, vitreous hemorrhage, conjunctival retraction, conjunctival erosion, and conjunctival bleb. Patients should be instructed to report signs or symptoms that could be associated with these events without delay. Additional surgical and/or medical management may be required. (5.1, 5.2, 5.3, 5.4, 5.5, 5.6, 5.7)
- <u>Vitreous Hemorrhage</u>: Temporarily discontinue antithrombotic medication prior to the implant insertion procedure to reduce the risk of vitreous hemorrhage. Vitrectomy may be needed. (5.5)
- <u>Postoperative Decrease in Visual Acuity</u>: A decrease in visual acuity usually occurs over the first two postoperative months. (5.8)

To report SUSPECTED ADVERSE REACTIONS, contact Genentech at 1-888-835-2555 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

See 17 for PATIENT COUNSELING INFORMATION and Medication Guide.

Revised: 2/2025

- 5.8 Postoperative Decrease in Visual Acuity
- 5.9 Air Bubbles Causing Improper Filling of the Implant
- 5.10 Deflection or Movement of the Implant

#### 6 ADVERSE REACTIONS

- 6.1 Clinical Trials Experience
- 8 USE IN SPECIFIC POPULATIONS
  - 8.1 Pregnancy
  - 8.2 Lactation
  - 8.3 Females and Males of Reproductive Potential
  - 8.4 Pediatric Use
  - 8.5 Geriatric Use
- 11 DESCRIPTION
- 12 CLINICAL PHARMACOLOGY
  - 12.1 Mechanism of Action
  - 12.3 Pharmacokinetics
  - 12.6 Immunogenicity
- 13 NONCLINICAL TOXICOLOGY
- 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility14 CLINICAL STUDIES
- 14.1 Neovascular (Wet) Age-Related Macular Degeneration (AMD)
   14.2 Diabetic Macular Edema (DME)
- 16 HOW SUPPLIED/STORAGE AND HANDLING
  - 16.1 How Supplied
  - 16.2 Storage
  - 16.3 Handling
- 17 PATIENT COUNSELING INFORMATION

\* Sections or subsections omitted from the full prescribing information are not list.

#### FULL PRESCRIBING INFORMATION

#### WARNING: ENDOPHTHALMITIS

The SUSVIMO implant has been associated with an up to 3-fold higher rate of endophthalmitis than monthly intravitreal injections of ranibizumab. Many of these events were associated with conjunctival retractions or erosions. Appropriate conjunctiva management and early detection with surgical repair of conjunctival retractions or erosions may reduce the risk of endophthalmitis. *[see Contraindications (4.1), Warnings and Precautions (5.1)].* 

#### **1** INDICATIONS AND USAGE

#### 1.1 Neovascular (wet) Age-related Macular Degeneration (AMD)

SUSVIMO (ranibizumab injection) is indicated for the treatment of patients with Neovascular (wet) Age-related Macular Degeneration (AMD) who have previously responded to at least two intravitreal injections of a Vascular Endothelial Growth Factor (VEGF) inhibitor medication.

#### 1.2 Diabetic Macular Edema (DME)

SUSVIMO (ranibizumab injection) is indicated for the treatment of patients with Diabetic Macular Edema (DME) who have previously responded to at least two intravitreal injections of a Vascular Endothelial Growth Factor (VEGF) inhibitor medication.

#### 2 DOSAGE AND ADMINISTRATION

#### 2.1 General Information

For Intravitreal Use via SUSVIMO ocular implant.

The SUSVIMO initial fill and ocular implant insertion and implant removal procedures must be performed under aseptic conditions by a physician experienced in vitreoretinal surgery. The SUSVIMO ocular implant must be surgically implanted in the eye or removed from the eye (if medically necessary) in an operating room using aseptic technique. See SUSVIMO Instructions for Use and the standardized steps to optimize surgical outcomes.

SUSVIMO refill-exchange procedures must be performed under aseptic conditions by a physician experienced in ophthalmic surgery [see Dosage and Administration (2.7)].

Do not administer SUSVIMO (ranibizumab injection) as a bolus intravitreal injection. Do not substitute SUSVIMO (ranibizumab injection) with other ranibizumab products.

<u>Initial Fill</u>: One SUSVIMO initial fill needle (34-gauge, with integrated 5  $\mu$ m filter and blue cap) is included. A 5-micron sterile filter needle (19-gauge x 1<sup>1</sup>/<sub>2</sub> inch), and a 1 mL Luer lock syringe are needed but **not included**.

<u>Refill-Exchange</u>: One SUSVIMO refill needle (34-gauge with integrated 5  $\mu$ m filter and clear cap) is included. A 5-micron sterile filter needle (19-gauge x 1<sup>1</sup>/<sub>2</sub> inch), and a 1 mL Luer lock syringe are needed but **not included**.

# 2.2 Neovascular (Wet) Age-Related Macular Degeneration (AMD) and Diabetic Macular Edema (DME)

The recommended dose of SUSVIMO (ranibizumab injection) is 2 mg (0.02 mL of 100 mg/mL solution) continuously delivered via the SUSVIMO ocular implant with refills administered every 24 weeks (approximately 6 months).

#### 2.3 Supplemental Treatment with Intravitreal Ranibizumab Injection


Supplemental treatment with 0.5 mg (0.05 mL of 10 mg/mL) intravitreal ranibizumab injection may be administered in the affected eye while the SUSVIMO implant is in place and if clinically necessary [see Clinical Studies (14)].

#### 2.4 Ocular Implant Initial Fill

The implant initial fill procedure must be performed by a physician experienced in vitreoretinal surgery [see Dosage and Administration (2.1)]. The implant will be filled using aseptic technique with 0.02 mL of SUSVIMO (ranibizumab injection) prior to insertion of the implant into the patient's eye [see Dosage and Administration (2.5)]. Refer to the complete SUSVIMO Instructions for Use for the initial fill and implant procedure included in the insertion tool assembly carton for further details.


Use aseptic technique to carry out the following preparation steps prior to insertion of the ocular implant into the patient's eye:


	Step 1: Gather the supplies needed.
	• One SUSVIMO ocular implant with
	insertion tool assembly (included)
	• One SUSVIMO initial fill needle
	(34-gauge with integrated 5 µm filter)
	with blue cap (included)
	• One SUSVIMO (ranibizumab injection)
	100 mg/mL vial (included)
	• One sterile 5-micron filter needle
	(19-gauge x 1 <sup>1</sup> / <sub>2</sub> inch) ( <b>not included</b> )
	• One sterile 1 mL Luer Lock syringe ( <b>not</b>
_	included)
Step 2: Transfer Dose from Vial to Syringe	
	Note: Use the filter needle (not included) to
	<b>Note:</b> Use the filter needle (not included) to withdraw SUSVIMO (ranibizumab
	injection) from the vial.
	injection/ nom the viai.
	<b>Do not</b> use the SUSVIMO initial fill needle
	for this step.
	Prepare SUSVIMO (ranibizumab



#### Step 5: Remove Any Remaining Air from Syringe


- With the initial fill needle attached, hold the syringe with the needle pointing up. If there are any air bubbles, gently tap the syringe with your finger until the bubbles rise to the top (see Figure 4).
- Slowly push the plunger rod just until all air is expelled from the syringe and needle, and a drop of drug solution is seen at the needle tip (see Figure 5).
- **Note:** It is important to preserve as much drug as possible in order to completely fill the implant.







#### Step 8: Fill Ocular Implant with SUSVIMO (ranibizumab injection) Under Microscope

- Under the microscope, <u>slowly</u> administer SUSVIMO (ranibizumab injection) into the ocular implant by slightly tilting the carrier upwards (see Figure 10).
- The ocular implant should be filled over approximately <u>5 to 10 seconds</u>, to help avoid air entrapment in the implant reservoir.
- Note: When filling the ocular implant, drug solution should only exit the ocular implant from the release control element. If drug solution is leaking from the implant at a different location, such as the side of the implant, do not use the ocular implant. If fluid is leaking from the septum at the needle insertion site, the needle may not be fully penetrating the implant septum. Fully push the syringe forward before continuing to fill the ocular implant.
- Continue filling the ocular implant until the implant is completely full of drug solution and all air has been expelled as evidenced by a dome of drug solution formed at the tip of the implant on the release control element (see Figure 11).







#### 2.5 Ocular Implant Insertion

SUSVIMO ocular implant insertion is a surgical procedure that is performed in an operating room. The procedure must be performed under aseptic conditions by a physician experienced in vitreoretinal surgery [see Dosage and Administration (2.1)].

The ocular implant is filled with SUSVIMO (ranibizumab injection) immediately prior to insertion. No more than 30 minutes should pass between the initial fill of the ocular implant and the insertion into the patient's eye.

After placing an infusion line in the eye, create at least a 6x6 mm peritomy of the conjunctiva and Tenon's capsule centered around the selected SUSVIMO implant location in the supero-temporal quadrant. Perform careful conjunctival incision, hemostasis of the underlying sclera, and generous undermining of Tenon's capsule. Using aseptic technique, fill the ocular implant [*see Dosage and Administration (2.4)*]. Using an MVR blade, create a full thickness dissection of the sclera 4 mm from the limbus until the pars plana is fully visible, with final target scleral incision length of 3.5 mm. Using a 532 nm laser endoprobe, apply contiguous, overlapping laser spots starting at 300 mW 1000 ms along the full length of the exposed pars plana and repeat until complete ablation is achieved. Pass a 3.2 mm slit knife perpendicularly through the center of the scleral dissection to open the underlying pars plana. Use the insertion tool to slowly insert the SUSVIMO implant into the sclero-pars plana incision perpendicular to the globe, ensuring that the long axis of the implant flange is properly aligned with the sclero-pars plana incision. Using the closed gripper tips of the insertion tool, seat the implant flush against the sclera. Clean any residual vitreous around the implant flange using a vitrector. Suture both Tenon's capsule and conjunctiva, using scleral anchoring at the apex of the peritomy,

ensuring complete coverage of the implant flange. Refer to the complete SUSVIMO Instructions for Use for the initial fill and implant procedure included in the insertion tool assembly carton for further details.

#### 2.6 Ocular Implant Removal

Removal of the SUSVIMO ocular implant is a surgical procedure that is performed in an operating room. The procedure must be performed under aseptic conditions by a physician experienced in vitreoretinal surgery [see Dosage and Administration (2.1)].

After placing an infusion line in the eye, create at least a 6x6 mm peritomy of the conjunctiva and Tenon's capsule around the SUSVIMO ocular implant flange. Remove any fibrous capsule or scar tissue that may have formed over the implant flange and septum using scalpel and forceps. With the explant tool oriented perpendicular to the globe, align the contoured tips with the long axis of the implant flange and grasp underneath the implant flange. Once the implant is secured in the explant tool, pull the implant from the eye in a perpendicular motion. Clear any vitreous prolapse present within or around the scleral wound using a vitrector. Completely close the scleral incision with multiple non-absorbable sutures. Close the Tenon's capsule and conjunctiva to completely cover the scleral incision. Refer to the complete Instructions for Use for the implant removal procedure included in the explant tool carton for further details.

#### 2.7 Ocular Implant Refill-Exchange Procedure

The SUSVIMO ocular implant refill-exchange procedure must be performed under strict aseptic conditions by a physician experienced in ophthalmic surgery [see Dosage and Administration (2.1)]. This includes the use of a surgical mask, sterile gloves, and a lid speculum.


Prior to and after the refill-exchange procedure, perform a dilated slit lamp exam and/or dilated indirect ophthalmoscopy to inspect the implant in the vitreous cavity through the pupil to identify if dislodgement of the implant septum has occurred [*see Figure 31 and Warnings and Precautions (5.4)*].

If the septum has dislodged, any further refill-exchange procedures should not be performed because normal device functioning cannot be assured. Discontinue treatment with SUSVIMO (ranibizumab injection) following septum dislodgement and consider implant removal should the benefit of the removal procedure outweigh the risk.


St	ep 1: Gather the supplies needed.
•	One SUSVIMO Refill Needle (34-gauge
	with a 5 µm integrated filter) with clear
	cap (included)
•	One SUSVIMO (ranibizumab injection)
	100 mg/mL vial (included)
•	One sterile 1 mL Luer Lock syringe (not
	included)
•	One sterile 5-micron filter needle (19-
	gauge x 1 <sup>1</sup> / <sub>2</sub> inch) ( <b>not included</b> )

<ul> <li>Prior to use in the clinic, inspect the packaging of the components for damage. Do not use if the sterility has been compromised or the contents have been dropped, damaged, or tampered with.</li> <li>Check the expiration date printed on the label.</li> <li>Remove the vial from the carton. Note: the outside of the vial is not sterile.</li> <li><u>Use aseptic technique</u> to open packaging and remove the <u>sterile refill needle</u> from the table.</li> </ul>	Sterile Field
<ul><li>the tray.</li><li>Inspect components and place onto sterile field (see Figure 16).</li></ul>	Figure 16
<ul> <li>field (see Figure 16).</li> <li>Step 3: Inspect SUSVIMO (ranibizumab injection)</li> <li>Visually inspect the contents of the SUSVIMO (ranibizumab injection) vial for particulate matter and discoloration.</li> </ul>	

Ste	p 4: Patient Preparation			
•	Dilate the pupil of the eye.			
•	Perform slit lamp examination and/or indirect ophthalmoscopy to inspect the implant and its components in the vitreous cavity through the dilated pupil.			
•	Position the patient on exam chair in the supine position at approximately 20° to 30° angle for optimal visualization of the implant.			
•	Apply a broad-spectrum microbicide to the periocular skin, eyelid, and ocular surface prior to the refill- exchange procedure. The use of a sterile drape is up to the physician's discretion.			
•	Perform the procedure under topical anesthesia.			
•	If needed, subconjunctival anesthesia may be administered in the nasal quadrant, away from the implant.			
Ste	p 5: Transfer Dose from Vial to Syringe			
Note: Use the filter needle to withdraw SUSVIMO (ranibizumab injection) from the vial.			Π	
<b>Do not</b> use the SUSVIMO refill needle for this step.				
• Prepare ranibizumab vial by removing the flip-off cap and disinfecting the rubber vial septum with alcohol.		+		
	Attach a filter needle to the syringe by screwing it tightly onto the Luer lock (see Figure 17).			
	Carefully remove the needle cap by pulling it straight off.		 Figure 17	1.00
•	Using aseptic technique, withdraw all of the contents of the SUSVIMO			



#### **Step 8: Remove Any Remaining Air from** Syringe and Adjust Drug Dose With the refill needle attached, hold the • syringe with the needle pointing up. Air bubble If there are any air bubbles, gently tap the • syringe with your finger until the bubbles rise to the top (see Figure 20). Figure 20 Slowly push the plunger rod until all air is • expelled from the syringe and needle and the uppermost edge of the black plunger tip is aligned with the **<u>0.1 mL</u>** dose mark 0.1mL (see Figure 21). Figure 21 **Step 9: Inspect the Syringe for Air Bubbles** Note: Ensure no air bubbles are present in the No air syringe and needle hub. Air injected bubble into the implant could result in slower drug release. No air bubble Inspect the syringe and the needle hub • using magnification to ensure that no air bubbles are present (see Figure 22). Note: Use the syringe within <u>15 minutes</u> of removing all air and adjusting the drug Figure 22



#### Step 11: Insert the Refill Needle


**Note:** Insert needle at the very center of the implant septum and perpendicular to the implant to ensure the needle inserts fully. **Do not** maneuver if there is resistance as it will bend the needle.

**Do not** use a bent refill needle; replace if bent or if damage is suspected.

- Targeting the center of the implant septum, insert the refill needle perpendicularly through the conjunctiva and into the implant septum (see Figure 25).
  - If excessive resistance, withdraw the refill needle. Orient and insert again.
  - Do not twist when encountering conjunctiva and Tenon's capsule to gain access to the septum, as damage to the overlying tissue and to the septum of the device may result.
- Continue inserting the needle until the soft stop of the refill needle makes physical contact with the conjunctiva (see Figure 26) to provide a tactile cue that optimal contact has been made.

#### Step 12: Refill the SUSVIMO Implant

- Refill the implant <u>slowly</u>, by delivering the entire contents of the syringe into the implant, over approximately <u>5 to 10</u>
   <u>seconds</u>, to avoid pressure build-up in the implant reservoir. The soft stop of the refill needle must remain in contact with the conjunctiva throughout the procedure.
- As ranibizumab is administered into the implant, existing solution from the implant should immediately begin to fill the refill needle fluid collection chamber (see Figure 27).



<ul> <li>If fluid is not observed collecting in the refill needle fluid collection reservoir, stop injecting and ensure the refill needle is inserted into the center of the implant septum at a perpendicular angle and the soft stop is in contact with the conjunctiva.</li> <li>Administer all of the syringe contents in order to achieve the target replacement ranibizumab concentration in the implant reservoir.</li> </ul>	
<ul> <li>Step 13: Withdraw the Syringe</li> <li>Withdraw the syringe perpendicular to the globe to avoid damaging the septum (see Figure 28).</li> <li>A cotton-tipped applicator may be used to provide counter traction to the conjunctiva during needle withdrawal.</li> </ul>	<image/>
Step 14: Dispose of the Used Components	1 iguit 20
• <b>Do not</b> recap the needle or detach it from the syringe. Dispose of the used syringe together with the refill needle in a sharps disposal container or in accordance with local requirements.	
<ul> <li>Step 15: Perform Indirect Ophthalmoscopy</li> <li>Perform dilated indirect ophthalmoscopy</li> </ul>	
• Perform diffated indiffect opininalitoscopy (and slit lamp exam as needed) to ensure continued proper position of the implant and its components (e.g., septum) in the vitreous cavity and to examine for complications.	

#### 2.8 Delayed or Missed Doses

If a planned dose (refill-exchange) of SUSVIMO (ranibizumab injection) is missed, it should be administered as soon as possible and the subsequent refill-exchange procedures should be performed 24 weeks (approximately 6 months) thereafter.

#### 2.9 Dosage (Refill-Exchange) Modifications for Adverse Reactions

Table 1 describes dosage modifications for specific adverse Reactions [see Warnings and *Precautions (5)]*. No dosage reductions for SUSVIMO are recommended.

Adverse Reactions	Dosage Modification		
Intraocular inflammation $\geq 1 + \text{cells or flare}$	Withhold dose (refill-exchange)		
Sight threatening events (e.g.,	Withhold dose (refill-exchange)		
rhegmatogenous retinal detachment, vitreous			
hemorrhage, unexplained vision loss, etc.)			
Local infections of either eye	Withhold dose (refill-exchange)		
Infectious endophthalmitis	Withhold dose (refill-exchange)		
Severe systemic infection	Withhold dose (refill-exchange)		
Observed damage to the implant	Withhold dose (refill-exchange) and consider		
	SUSVIMO implant removal [see Dosage and		
	Administration (2.7, 2.8)].		

 Table 1: Dosage (Refill-Exchange) Modifications for Adverse Reactions

#### **3 DOSAGE FORMS AND STRENGTHS**

Injection: 100 mg/mL, clear to slightly opalescent, colorless to pale brown solution in a single-dose vial

#### 4 CONTRAINDICATIONS

#### 4.1 Ocular or Periocular Infections

SUSVIMO (ranibizumab injection) is contraindicated in patients with ocular or periocular infections.

#### 4.2 Active Intraocular Inflammation

SUSVIMO (ranibizumab injection) is contraindicated in patients with active intraocular inflammation.

#### 4.3 Hypersensitivity

SUSVIMO (ranibizumab injection) is contraindicated in patients with known hypersensitivity to ranibizumab products or any of the excipients in SUSVIMO (ranibizumab injection).

#### 5 WARNINGS AND PRECAUTIONS

The SUSVIMO implant and/or implant-related procedures have been associated with endophthalmitis, rhegmatogenous retinal detachment, implant dislocation, septum dislodgement, vitreous hemorrhage, conjunctival erosion, conjunctival retraction, and conjunctival blebs. Patients should be instructed to report any signs or symptoms that could be associated with these events without delay. In some cases, these events can present asymptomatically. The implant and the tissue overlying the implant flange should be monitored routinely following the implant insertion, and refill-exchange procedures to permit early medical or surgical intervention as necessary. Special precautions need to be taken when handling SUSVIMO components [see How Supplied/Storage and Handling (16.3)].

#### 5.1 Endophthalmitis

In the active comparator period of controlled clinical trials in AMD, the ranibizumab implant has been associated with a 3-fold higher rate of endophthalmitis than monthly intravitreal injections of ranibizumab (1.7% in the SUSVIMO arm vs 0.5% in the intravitreal arm). When including extension phases of clinical trials, 2% (11/555) of patients receiving the ranibizumab implant experienced an episode of endophthalmitis. Reports occurred between days 5 and 853, with a median of 173 days. Many, but not all, of the cases of endophthalmitis reported a preceding or concurrent conjunctival retraction or erosion event.

In the active comparator period of the controlled clinical trial in DME, 0% of patients in the SUSVIMO arm compared to 0.3% in the intravitreal arm experienced an episode of endophthalmitis. When including the extension phase of the clinical trial, 0.7% (4/556) of patients receiving the ranibizumab implant experienced an episode of endophthalmitis. Reports occurred between days 625 and 1016, with a median of 824 days.

Endophthalmitis should be treated promptly in an effort to reduce the risk of vision loss and maximize recovery. The SUSVIMO (ranibizumab injection) dose (refill-exchange) should be delayed until resolution of endophthalmitis [see Dosage and Administration (2.9) and Adverse Reactions (6.1)].

Patients should not have an active or suspected ocular or periocular infection or severe systemic infection at the time of any SUSVIMO implant or refill procedure. Appropriate intraoperative handling followed by secure closure of the conjunctiva and Tenon's capsule, and early detection and surgical repair of conjunctival erosions or retractions and strict/controlled aseptic technique conditions throughout refill-exchange procedures may reduce the risk of endophthalmitis [see Dosage and Administration (2.1) and Warnings and Precautions (5.5)].

#### 5.2 Rhegmatogenous Retinal Detachment

Rhegmatogenous retinal detachments have occurred in clinical trials of SUSVIMO and may result in vision loss. Rhegmatogenous retinal detachments should be promptly treated with an intervention (e.g., pneumatic retinopexy, vitrectomy, or laser photocoagulation). SUSVIMO (ranibizumab injection) dose (refill-exchange) should be delayed in the presence of a retinal detachment or retinal break [see Dosage and Administration (2.9)].

Careful evaluation of the retinal periphery is recommended to be performed, and any suspected areas of abnormal vitreo-retinal adhesion or retinal breaks should be treated before inserting the implant in the eye.

#### 5.3 Implant Dislocation

In clinical trials, the device has dislocated/subluxated into the vitreous cavity or has extended outside the vitreous cavity into or beyond the subconjunctival space. Device dislocation requires urgent surgical intervention. Strict adherence to the scleral incision length and appropriate targeting of the pars plana during laser ablation may reduce the risk of implant dislocation.

#### 5.4 Septum Dislodgement

In clinical trials, a type of implant damage where the septum has dislodged into the implant body has been reported. Perform a dilated slit lamp exam and/or dilated indirect ophthalmoscopy to inspect the implant in the vitreous cavity through the pupil prior to and after the refill-exchange procedure to identify if septum dislodgement has occurred. Discontinue treatment with SUSVIMO (ranibizumab injection) following septum dislodgement and consider implant removal should the benefit of the removal procedure outweigh the risk [see Dosage and Administration (2.8)].

Appropriate handling and insertion of the refill needle into the septum (avoid twisting and/or rotation) is required to minimize the risk of septum dislodgement [see Dosage and Administration (2.7)].

#### 5.5 Vitreous Hemorrhage

Vitreous hemorrhages may result in temporary vision loss. Vitrectomy may be needed in the case of a non-clearing vitreous hemorrhage [see Dosage and Administration (2.9)].

In clinical trials of SUSVIMO including extension phases in patients with AMD, vitreous hemorrhages were reported in 5.2% (23/443) of patients receiving SUSVIMO.

In the clinical trial of SUSVIMO including extension phases in patients with DME, vitreous hemorrhages were reported in 10.1% (56/556) of patients receiving SUSVIMO.

The majority of these hemorrhages occurred within the first post-operative month following surgical implantation and the majority of vitreous hemorrhages resolved spontaneously.

Patients on antithrombotic medication (e.g., oral anticoagulants, aspirin, nonsteroidal antiinflammatory drugs) may be at increased risk of vitreous hemorrhage. Antithrombotic medications are recommended to be temporarily interrupted prior to the implant insertion procedure. The SUSVIMO (ranibizumab injection) dose (refill-exchange) should be delayed in the event of sight-threatening vitreous hemorrhage. The use of pars plana laser ablation and scleral cauterization should be performed to reduce the risk of vitreous hemorrhage.

#### 5.6 Conjunctival Erosion or Retraction

A conjunctival erosion is a full thickness degradation or breakdown of the conjunctiva in the area of the implant flange. A conjunctival retraction is a recession or opening of the limbal and/or radial peritomy. Conjunctival erosions or retractions have been associated with an increased risk of endophthalmitis, especially if the implant becomes exposed. Surgical intervention (e.g., conjunctival/Tenon's capsule repair) is recommended to be performed in case of conjunctival erosion or retraction with or without exposure of the implant flange.

In clinical trials of SUSVIMO including extension phases in patients with AMD, 3.6% (16/443) of patients receiving SUSVIMO reported conjunctival erosion and 1.6% (7/443) of patients receiving SUSVIMO reported conjunctival retraction in the study eye.

In the clinical trial of SUSVIMO including extension phases of patients with DME, 2.2% (12/556) of patients receiving SUSVIMO reported conjunctival erosion and 1.3% (7/556) of patients receiving SUSVIMO reported conjunctival retraction in the study eye.

Appropriate intraoperative handling of conjunctiva and Tenon's capsule to preserve tissue integrity and secure closure of peritomy while ensuring placement of sutures away from implant edge may reduce the risk of conjunctival erosion or retraction. The implant and the tissue overlying the implant flange should be monitored routinely following the implant insertion.

#### 5.7 Conjunctival Bleb

A conjunctival bleb is an encapsulated elevation of the conjunctiva above the implant flange, which may be secondary to subconjunctival thickening or fluid. Conjunctival blebs may require surgical management to avoid further complications, especially if the implant septum is no longer identifiable due to the conjunctival bleb.

In clinical trials of SUSVIMO including extension phases in patients with AMD, 5.9% (26/443) of patients receiving SUSVIMO reported conjunctival bleb/conjunctival filtering bleb leak in the study eye.

In the clinical trial of SUSVIMO including extension phases in patients with DME, 9% (50/556) of patients receiving SUSVIMO reported conjunctival bleb/conjunctival filtering bleb leak in the study eye.

Strict adherence to the scleral incision length, appropriate intraoperative handling of conjunctiva and Tenon's capsule to preserve tissue integrity and secure closure of peritomy, and proper seating of the refill needle during refill-exchange procedures may reduce the risk of conjunctival bleb.

#### 5.8 Postoperative Decrease in Visual Acuity

Visual acuity was decreased by 4 letters on average in the first postoperative month and 2 letters on average in the second postoperative month following initial implantation of SUSVIMO in patients with AMD [see Clinical Studies (14.1)].

Visual acuity was decreased by 7 letters on average in the first postoperative month and 3 letters on average in the second postoperative month following initial implantation of SUSVIMO in patients with DME [see Clinical Studies (14.2)].

#### 5.9 Air Bubbles Causing Improper Filling of the Implant

Minimize air bubbles within the implant reservoir as they may cause slower drug release. During the initial fill procedure, if an air bubble is present, it must be no larger than 1/3 of the widest diameter of the implant. If excess air is observed after initial fill, **do not** use the implant. During the refill-exchange procedure, if excess air is present in the syringe and needle **do not** use the syringe and needle. If excess air bubbles are observed after the refill-exchange procedure, consider repeating the refill-exchange procedure.

#### 5.10 Deflection or Movement of the Implant

Use caution when performing ophthalmic procedures (e.g., B-scan ophthalmic ultrasound, scleral depression, or gonioscopy) that may cause deflection or movement of the implant and subsequent injury.

#### 6 ADVERSE REACTIONS

The following adverse reactions are discussed in greater detail in other sections of the label:

- Endophthalmitis [see Warnings and Precautions (5.1)]
- Rhegmatogenous Retinal Detachment [see Warnings and Precautions (5.2)]
- Implant Dislocation [see Warnings and Precautions (5.3)]
- Septum Dislodgement [see Warnings and Precautions (5.4)]
- Vitreous Hemorrhage [see Warnings and Precautions (5.5)]
- Conjunctival Erosion or Retraction [see Warnings and Precautions (5.6)]
- Conjunctival Bleb [see Warnings and Precautions (5.7)]
- Postoperative Decrease in Visual Acuity [see Warnings and Precautions (5.8)]

#### 6.1 Clinical Trials Experience

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in one clinical trial of a drug cannot be directly compared with rates in the clinical trials of the same or another drug and may not reflect the rates observed in practice.

The data below (Table 2) reflect exposure of 248 patients with AMD in the Archway study up to Week 40, and 320 patients with DME in the Pagoda study up to Week 64 following the SUSVIMO initial fill and implant insertion, refill, and implant removal (if necessary) procedures. In the AMD patient population the most common ( $\geq 10\%$ ) adverse reactions up to Week 40 were conjunctival hemorrhage (72%), conjunctival hyperemia (26%), iritis (23%), and eye pain (10%). Septum dislodgement was reported in 0.4% of the AMD patient population.

In the DME patient population the most common ( $\geq 10\%$ ) adverse reactions up to Week 64 were conjunctival hemorrhage (62%), conjunctival hyperemia (15%), iritis (14%), eye pain (13%), cataract (11%), conjunctival disorder (10%) and vitreous hemorrhage (10%).

Adverse Reactions	AN Wee		DME Week 64		
	SUSVIMO n = 248	Intravitreal ranibizumab n = 167	SUSVIMO n = 320	Intravitreal ranibizumab 0.5 mg n = 314	
Conjunctival hemorrhage	72%	6%	62%	18%	
Conjunctival hyperemia	26%	2%	15%	0	
Iritis <sup>1</sup>	23%	0.6%	14%	2%	
Eye pain	10%	5%	13%	6%	
Conjunctival disorder <sup>2</sup>	9%	0	10%	0.3%	
Vitreous floaters	9%	2%	4%	5%	
Conjunctival bleb/ filtering bleb leak <sup>3</sup>	8%	0	8%	0	
Foreign body sensation in eyes	7%	1%	3%	2%	
Headache <sup>4</sup>	6%	2%	6%	4%	
Hypotony of eye	6%	0	3%	0	
Vitreous detachment	6%	5%	8%	5%	
Vitreous hemorrhage	5%	2%	10%	2%	
Cataract <sup>5</sup>	4%	4%	11%	7%	
Corneal disorder	4%	0	1%	0	
Corneal abrasion <sup>6</sup>	4%	0.6%	4%	1%	
Corneal edema	4%	0	4%	0.3%	

#### Table 2Adverse Reactions occurring in $\geq 4\%$ of patients in the SUSVIMO arm

<sup>1</sup> Iritis includes: iritis, anterior chamber flare, anterior chamber inflammation, and anterior chamber cell.

<sup>2</sup> Conjunctival disorder includes: conjunctival adhesion, conjunctival disorder, conjunctival edema, conjunctival erosion, conjunctival retraction, and subconjunctival fibrosis.

- <sup>3</sup> Conjunctival bleb/filtering bleb leak includes: conjunctival bleb, conjunctival filtering bleb leak, conjunctival cyst, subconjunctival cyst, and implant site cyst.
- <sup>4</sup> Headache includes: headache and procedural headache.
- <sup>5</sup> Cataract includes: cataract, cortical cataract, nuclear cataract, and subcapsular cataract.
- <sup>6</sup> Corneal abrasion includes: corneal abrasion and vital dye staining cornea present.

#### 8 USE IN SPECIFIC POPULATIONS

#### 8.1 Pregnancy

#### Risk Summary

There are no adequate and well-controlled studies of SUSVIMO (ranibizumab injection) administration in pregnant women. Administration of ranibizumab to pregnant monkeys throughout the period of organogenesis resulted in a low incidence of skeletal abnormalities at intravitreal doses up to 41 times the human exposure (based on serum levels following the recommended clinical dose). No skeletal abnormalities were observed at serum trough levels

similar to the human exposure after a single eye treatment at the recommended clinical dose (*see Data*).

Animal reproduction studies are not always predictive of human response, and it is not known whether ranibizumab can cause fetal harm when administered to a pregnant woman. Based on the anti-VEGF mechanism of action for ranibizumab [see Clinical Pharmacology (12.1)], treatment with SUSVIMO (ranibizumab injection) may pose a risk to human embryofetal development.

All pregnancies have a background risk of birth defects, loss, and other adverse outcomes. The background risk of major birth defects and miscarriage for the indicated population is unknown. In the U.S. general population, the estimated background risk of major birth defects is 2% - 4% and of miscarriage is 15% - 20% of clinically recognized pregnancies.

## <u>Data</u>

### Animal Data

An embryo-fetal developmental toxicity study was performed on pregnant cynomolgus monkeys. Pregnant animals received intravitreal injections of ranibizumab every 14 days starting on Day 20 of gestation, until Day 62 at doses of 0, 0.125, and 1 mg/eye. Skeletal abnormalities including incomplete and/or irregular ossification of bones in the skull, vertebral column, and hindlimbs and shortened supernumerary ribs were seen at a low incidence in fetuses from animals treated with 1 mg/eye of ranibizumab. The 1 mg/eye dose resulted in trough serum ranibizumab levels up to 41 times higher than observed human  $C_{max}$  levels of SUSVIMO (ranibizumab injection) after treatment of a single eye.

No skeletal abnormalities were seen at the lower dose of 0.125 mg/eye, a dose which resulted in trough exposures similar to single eye treatment with SUSVIMO (ranibizumab injection) in humans. No effect on the weight or structure of the placenta, maternal toxicity, or embryotoxicity was observed.

### 8.2 Lactation

### Risk Summary

There are no data available on the presence of ranibizumab in human milk, the effects of ranibizumab on the breastfed infant or the effects of ranibizumab on milk production/excretion. Because many drugs are excreted in human milk, and because the potential for absorption and harm to infant growth and development exists, caution should be exercised when SUSVIMO is administered to a nursing woman.

The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for SUSVIMO (ranibizumab injection) and any potential adverse effects on the breastfed child from ranibizumab.

## 8.3 Females and Males of Reproductive Potential

### **Contraception**

Females of reproductive potential should use effective contraception during treatment with SUSVIMO (ranibizumab injection) and for at least 12 months after the last dose of SUSVIMO

(ranibizumab injection).

## **Infertility**

No studies on the effects of ranibizumab on fertility have been conducted and it is not known whether ranibizumab can affect reproduction capacity. Based on the anti-VEGF mechanism of action for ranibizumab, treatment with SUSVIMO (ranibizumab injection) may pose a risk to reproductive capacity.

## 8.4 Pediatric Use

The safety and efficacy of SUSVIMO (ranibizumab injection) in pediatric patients have not been established.

## 8.5 Geriatric Use

In the Archway study, 90% (222 of 248) of the patients randomized to treatment with SUSVIMO were  $\geq 65$  years old and approximately 57% (141 of 248) were  $\geq 75$  years old. No notable difference in treatment effect or safety was seen with increasing age.

## **11 DESCRIPTION**

Ranibizumab is a recombinant humanized IgG1 kappa isotype monoclonal antibody fragment for intraocular use. Ranibizumab binds to and inhibits the biologic activity of human vascular endothelial growth factor-A (VEGF-A). Ranibizumab, which lacks an Fc region, has a molecular weight of approximately 48 kilodaltons and is produced by an *E. coli* expression system in a nutrient medium containing the antibiotic tetracycline. Tetracycline is not detectable in the final product.

SUSVIMO (ranibizumab injection) is supplied as a sterile, clear to slightly opalescent, colorless to pale brown solution for intravitreal use via the SUSVIMO implant. Each single-dose vial contains 10 mg of ranibizumab, histidine HCl (0.1 mg), polysorbate 20 (0.01 mg), sucrose (8.2 mg), and Water for Injection, in 0.1 mL of solution with a pH of 5.5. The SUSVIMO implant is designed to contain approximately 0.02 mL (2 mg) of ranibizumab solution when filled. SUSVIMO does not contain an antimicrobial preservative.

## 12 CLINICAL PHARMACOLOGY

## 12.1 Mechanism of Action

Ranibizumab binds to the receptor binding site of multiple biologically active forms of VEGF-A, including VEGF<sub>110</sub>. VEGF-A has been shown to cause neovascularization and leakage in models of ocular angiogenesis and vascular occlusion and is thought to contribute to pathophysiology of neovascular AMD. The binding of ranibizumab to VEGF-A prevents the interaction of VEGF-A with its receptors (VEGFR1 and VEGFR2) on the surface of endothelial cells, reducing endothelial cell proliferation, vascular leakage, and new blood vessel formation.

## 12.3 Pharmacokinetics

The SUSVIMO implant provides a continuous release of ranibizumab where the release of ranibizumab into the vitreous decreases over time as the concentration in the implant decreases. The ranibizumab serum and aqueous humor concentrations with a SUSVIMO 24-week treatment interval are maintained below the maximum and above the minimum concentrations experienced

with monthly 0.5 mg intravitreal ranibizumab.

#### **Distribution**

Ranibizumab is distributed from the vitreous to the aqueous humor and serum. The ranibizumab concentrations in aqueous humor decrease with a half-life of approximately 15 weeks. The ranibizumab serum concentrations decrease with a half-life of approximately 29 weeks. Ranibizumab did not accumulate in serum when administered with refills every 24 weeks.

Following implant insertion of SUSVIMO in patients with AMD, the mean ( $\pm$ SD) maximum ranibizumab serum concentration ( $C_{max}$ ) was 0.48 ( $\pm$ 0.17) ng/mL and median (range) time to maximum serum concentration ( $T_{max}$ ) was 26 (1 – 89) days. Following the initial fill and refill of SUSVIMO in patients, maximum serum concentrations of ranibizumab were below the ranibizumab concentration necessary to inhibit the biological activity of VEGF by 50%.

#### **Elimination**

#### Metabolism

The metabolism of SUSVIMO (ranibizumab injection) has not been studied. SUSVIMO (ranibizumab injection) is a monoclonal antibody fragment and antibodies are cleared principally by catabolism.

#### Excretion

The full excretion profile for ranibizumab following administration of SUSVIMO is unknown.

#### Specific Populations

Patients with renal impairment were included in the population pharmacokinetic analysis of SUSVIMO (ranibizumab injection). For patients analyzed, 60% (393 of 659) had renal impairment (34% mild [CrCL 60 to 89 mL/min], 24% moderate [CrCL 30 to 59 mL/min] and 2% severe [CrCL < 30 mL/min]). Across all indications, systemic clearance of ranibizumab was slightly lower in renally impaired patients but was not clinically significant. No clinically significant differences in the pharmacokinetics of ranibizumab were observed based on age in the patient population.

### 12.6 Immunogenicity

As with all therapeutic proteins, there is potential for immune response in patients treated with ranibizumab including SUSVIMO. The detection of an immune response is highly dependent on the sensitivity, specificity, and drug tolerance level of the assay. Additionally, the observed incidence of antibody positivity in an assay may be influenced by several factors including assay methodology, sample handling, timing of sample collection, concomitant medications, and underlying disease. For these reasons, comparison of the incidence of antibodies in the study described below with the incidence of antibodies in other studies or to other products may be misleading.

Prior to treatment with SUSVIMO, 2.1-3.6% of patients with AMD or DME tested positive for anti-ranibizumab antibodies. In patients with AMD, after the SUSVIMO implant insertion and treatment, 12% (29 of 247) patients tested positive for anti-ranibizumab antibodies. In patients with DME, after 4 doses of intravitreal ranibizumab and SUSVIMO implant insertion and treatment, 13% (41 of 320) patients tested positive for anti-ranibizumab antibodies. No clinically

meaningful differences in the pharmacokinetics, efficacy, or safety in patients testing positive for anti-ranibizumab antibodies were observed.

## 13 NONCLINICAL TOXICOLOGY

## 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

No studies have been conducted to determine the carcinogenic or mutagenic potential of SUSVIMO (ranibizumab injection). Based on the anti-VEGF mechanism of action for ranibizumab, treatment with SUSVIMO (ranibizumab injection) may pose a risk to reproductive capacity [see Females and Males of Reproductive Potential (8.3)].

## 14 CLINICAL STUDIES

## 14.1 Neovascular (wet) Age-related Macular Degeneration (AMD)

The clinical efficacy and safety of SUSVIMO (ranibizumab injection) was assessed in a randomized, visual assessor-masked, active treatment-controlled study (Archway-NCT03677934) in patients with AMD. A total of 415 patients (248 in the SUSVIMO arm and 167 in the intravitreal ranibizumab arm) were enrolled and treated in this study. Patients were diagnosed with AMD within the 9 months prior to screening and received  $\geq$  3 doses of anti-VEGF intravitreal agents in the study eye within the last 6 months prior to screening. Each patient was required to have demonstrated a response to an anti-VEGF intravitreal agent prior to randomization. Patients were randomized in a 3:2 ratio to receive continuous delivery of SUSVIMO (ranibizumab injection) via the SUSVIMO implant every 24 weeks or 0.5 mg intravitreal ranibizumab injections every 4 weeks. For patients randomized to the SUSVIMO arm, supplemental treatment with 0.5 mg intravitreal ranibizumab injections was available at Weeks 16, 20, 40, 44, 64, 68, 88, and 92, if needed. In the first 24 weeks, 1.6% of patients assessed for supplemental treatment received 1 or more supplemental treatment(s).

The primary efficacy endpoint of change from baseline in distance Best Corrected Visual Acuity (BCVA) score averaged over Week 36 and Week 40 demonstrated that SUSVIMO was equivalent to intravitreal ranibizumab injections administered every 4 weeks. Detailed efficacy results are shown in Table 3 and Figure 29 below.

Table 5 Visual Acuity outcomes at week 40 m Archway (GR40546) Study				
Outcome Measure*	SUSVIMO (100 mg/mL) n=248	Intravitreal ranibizumab 0.5 mg (10 mg/mL) n=167	Difference (95% CI)**	
Adjusted Mean change from baseline in BCVA score averaged over Weeks 36 and 40	0.2	0.5	-0.3 (-1.7, 1.1)***	


### Table 3Visual Acuity outcomes at Week 40 in Archway (GR40548) Study


BCVA = Best corrected visual acuity

\* BCVA measured using the Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity chart at a starting distance of 4 meters.

\*\* All estimates are adjusted estimates based on a mixed-effect model with repeated measures. SUSVIMO arm - intravitreal ranibizumab arm. 95% is a rounding of 95.03% CI; The type 1 error was adjusted for interim sensitivity monitoring.

\*\*\* Equivalence margins were ±4.5 letters.





\* Prior to study treatment, a median of 4 doses of anti-VEGF intravitreal agents were administered in the study eye of patients in the SUSVIMO and intravitreal ranibizumab arms.

\*\* Decrease in BCVA at Week 4 during post-operative recovery period.

Q24W = every 24 weeks; Q4W = every 4 weeks

Consistent results were observed across patient subgroup analyses for mean change from baseline in BCVA score (age, gender, number of prior anti-VEGF intravitreal injections, and baseline BCVA score).

#### 14.2 Diabetic Macular Edema (DME)

The clinical efficacy and safety of SUSVIMO were assessed in a randomized, visual assessor-masked, active treatment-controlled study [Pagoda (GR40550) NCT04108156] in patients with DME. A total of 634 patients (381 in the SUSVIMO arm and 253 in the intravitreal ranibizumab 0.5 mg arm) were enrolled and treated in this study. Patients were randomized in a 3:2 ratio to receive continuous delivery of SUSVIMO via the implant every 24 weeks or 0.5 mg intravitreal ranibizumab injections every 4 weeks.

Prior to study treatment, a median of 4 doses of intravitreal ranibizumab 0.5 mg were administered in the study eye of patients in the SUSVIMO and intravitreal ranibizumab arms. Patient ages ranged from 29 to 89 years with a mean of 60.7 years. A total of 21%


of patients were previously treated for DME. At baseline, the overall mean visual acuity was 65.3 letters (range: 25 to 89 letters).


The primary efficacy endpoint of change from baseline in distance Best Corrected Visual Acuity (BCVA) score averaged over Week 60 and Week 64 demonstrated that SUSVIMO was non-inferior to intravitreal ranibizumab injections administered every 4 weeks. Detailed efficacy results are shown in Table 4 and Figure 30 below.

#### Table 4Key efficacy outcomes at Week 60 and Week 64 in the Pagoda (GR40550) Study

Outcome Measure*	SUSVIMO	Intravitreal	Difference
	100 mg/mL	ranibizumab 0.5 mg	(95% CI)**
		(10 mg/mL)	
	n=381		
		n=253	
Change in BCVA scores			
from baseline averaged			
over Week 60 and Week 64			
Adjusted Mean	9.6	9.4	0.2 (-1.2, 1.6)

BCVA = Best corrected visual acuity





⊖ Intravitreal Ranibizumab 0.5 mg (N=253) 🖶 Susvimo 100 mg/mL (N=381)

Consistent results were observed across patient subgroup analyses for mean change from baseline in BCVA score (age, ethnicity, gender, baseline HbA1c score, focal/macular laser

history, baseline BCVA score, prior intravitreal anti-VEGF treatment and DR severity).

## 16 HOW SUPPLIED/STORAGE AND HANDLING


## 16.1 How Supplied

Each SUSVIMO initial fill needle kit (NDC 50242-078-55) contains:

- One SUSVIMO 100 mg/mL single-dose glass vial
- One SUSVIMO initial fill needle (34-gauge needle with a 5 μm integrated filter) with a blue cap

Each SUSVIMO (ranibizumab injection) carton (NDC 50242-078-12) contains one SUSVIMO (ranibizumab injection) 100 mg/mL that is clear to slightly opalescent, colorless to pale brown solution in a single-dose glass vial.

Each SUSVIMO refill needle carton contains a SUSVIMO refill needle (34-gauge vented needle with a 5  $\mu$ m integrated filter) with a clear cap.





## SUSVIMO implant

- SUSVIMO implant (Figure 31) is capable of holding 0.02 mL of drug, and is secured within the sclera, by the extrascleral flange that remains visible through the conjunctiva following insertion.
- The septum is a self-sealing interface through which ranibizumab is administered to fill the implant.

# SUSVIMO (ranibizumab injection) 100 mg/mL vial

• SUSVIMO (ranibizumab injection) (Figure 32) is used to fill the implant with ranibizumab prior to insertion or during subsequent refill-exchange in an officebased setting.







Figure 33

### SUSVIMO refill needle

 SUSVIMO refill needle (Figure 33) consists of a 34 G vented needle assembly, silicone soft stop, and a 5 µm integrated filter within the needle hub. It is designed to simultaneously exchange the contents of the implant reservoir with replacement ranibizumab in an office-based setting. As replacement ranibizumab is administered into the implant through the stainless-steel cannula, fluid remaining in the implant flows through openings in the vented needle and is collected in the fluid collection reservoir.





• SUSVIMO refill needle is distinguished by its clear cap.

#### **Materials List**

Materials that are required and supplied to perform the procedure are:

- SUSVIMO refill needle, 34 G, with clear cap
- SUSVIMO (ranibizumab injection) 100 mg/mL

Additional materials required to perform the procedure but are not provided are:

- One sterile 1 mL Luer Lock syringe (not included)
- One sterile 5-micron filter needle (19-gauge x 1<sup>1</sup>/<sub>2</sub> inch) (**not included**)
- Anesthetic ophthalmic solutions
- Ophthalmic broad-spectrum microbicide solution
- Cotton tips and gauze
- Sterile powder free gloves
- Face masks
- Lid speculum
- Magnification such as visor or loupes
- Task lighting
- Indirect ophthalmoscope and lens
- Sterile drape (*optional for refill-exchange procedure*)

#### 16.2 Storage

Store SUSVIMO initial fill needle kit at 2°C to 8°C (36°F to 46°F). **Do not** freeze. Protect from light. **Do not** shake. The SUSVIMO initial fill needle has been sterilized with electron beam processing.

Store SUSVIMO (ranibizumab injection) 100 mg/ mL vial at  $2^{\circ}$ C to  $8^{\circ}$ C ( $36^{\circ}$ F to  $46^{\circ}$ F). **Do not** freeze. Protect from light. **Do not** shake. Prior to use, the unopened vial may be kept at  $9^{\circ}$ C to  $30^{\circ}$ C ( $48^{\circ}$ F to  $86^{\circ}$ F) for up to 24 hours provided it is protected from light.

Store the SUSVIMO implant and insertion tool assembly, refill needle and explant tool at room temperature 15°C to 25°C (59°F to 77°F). The SUSVIMO implant and insertion tool assembly has been sterilized with ethylene oxide gas. The SUSVIMO refill needle and explant tool have been sterilized with electron beam processing.

## 16.3 Handling

SUSVIMO components are supplied sterile and are for single-use only. Do not reprocess, re-sterilize, or reuse SUSVIMO components. Do not use if the sterility has been compromised or the contents have been dropped, damaged or tampered with. Do not use past the expiration date printed on the label. Do not open sealed tray until time of use. Avoid contact between sharp surgical instruments and the SUSVIMO implant as the material of the septum and silicone encasing is soft and susceptible to damage.

## **Important Device Handling Information**

• Use caution when performing ophthalmic procedures (e.g., B-scan ophthalmic ultrasound, scleral depression, or gonioscopy) that may cause deflection or movement of the implant and subsequent injury.

Ocular Implant Initial Fill Procedure

• Minimize air bubbles within the implant reservoir as they may cause slower drug release. If an air bubble is present, it must be no larger than 1/3 of the widest diameter of the implant. If excess air is observed after initial fill, **do not** use the implant.

Ocular Implant Insertion Procedure

- Perpendicular entry of the implant is important to avoid contact between the implant and intraocular structures such as the lens, as contact between the implant and the intraocular structures may cause adverse reactions such as traumatic cataract.
- Avoid excessive force on the globe by first ensuring that the tip of the implant has passed through the sclero-pars plana incision before slowly pushing the implant into place.

Ocular Implant Removal Procedure

• **Do not** grasp the implant by the short axis of the implant flange. Remove the implant in a gentle manner. Perpendicular exit of the implant is important to avoid contact between the implant and intraocular structures such as the lens.

## 17 PATIENT COUNSELING INFORMATION

Advise the patient to read the FDA-approved patient labeling (Medication Guide).

## Advise patients on the following after the implant insertion procedure:

Positioning:

- Keep head above shoulder level for the rest of the day.
- Sleep with head on 3 or more pillows during the day and the night after surgery.

How to care for the treated eye after the procedure:

- Do not remove the eye shield until they are instructed to do so by their healthcare provider. At bedtime, continue to wear the eye shield for at least 7 nights following the implant surgery.
- Administer all post-operative eye medications as directed by their healthcare provider.
- Do not push on the eye, rub the eye, or touch the area of the eye where the implant is located (underneath the eyelid in the upper and outer part of the eye) for 30 days following the implant insertion.
- Do not participate in strenuous activities until 1-month after the implant insertion or after discussion with their healthcare provider.

Magnetic Resonance (MR) Conditional information:

• The SUSVIMO implant is MR conditional. Inform their healthcare provider that they have SUSVIMO implanted in their eye and show their healthcare provider the SUSVIMO implant card should they require Magnetic resonance imaging (MRI).

Advise patients on the following after the Refill-Exchange procedure:

- Refrain from pushing on the treated eye, rubbing the eye, or touching the eye in the area of the implant (located underneath the eyelid in the upper and outer part of your eye) for 7 days following the refill-exchange procedure.
- Administer eye drops as directed by their healthcare provider.

Advise patients on the following after the implant removal procedure (if it is deemed medically necessary):

- Keep your head above shoulder level for the rest of the day.
- Sleep with your head on 3 or more pillows if lying down during the day and night after the implant removal.
- Wear an eye shield for at least 7 nights following the implant removal.
- Do not participate in strenuous activities until 14 days following the implant removal.
- Administer all post-operative anti-inflammatory and antimicrobial drops, as directed by your healthcare provider.

Advise patients on the following throughout SUSVIMO treatment:

- Do not drive or use machinery until the eye shield can be removed and visual function has recovered sufficiently [see Adverse Reactions (6.1)].
- The SUSVIMO implant and/or implant related procedures have been associated with conjunctival reactions (bleb, erosion, retraction), vitreous hemorrhage, endophthalmitis, rhegmatogenous retinal detachment, the dislocation of the implant, septum dislodgement, and a temporary decrease in vision.
- While the implant is in the eye, avoid rubbing the eye or touching the area as much as possible. However, if necessary to do so, make sure hands are cleaned prior to touching the eye.

• Seek immediate care from an ophthalmologist if there are sudden changes in their vision (an increase in moving spots, the appearance of "spider webs", flashing lights, or a loss in vision), increasing eye pain, progressive vision loss, sensitivity to light, redness in the white of the eye, a sudden sensation that something is in their eye, or eye discharge or watering [see Warnings and Precautions (5)].

SUSVIMO<sup>®</sup> [ranibizumab injection] Manufactured by: Genentech, Inc. A Member of the Roche Group 1 DNA Way South San Francisco, CA 94080-4990 U.S. License No.: 1048

SUSVIMO is a registered trademark of Genentech, Inc. ©2025 Genentech, Inc.

#### MEDICATION GUIDE SUSVIMO<sup>®</sup> (suss-VIH-moh) (ranibizumab injection) for intravitreal use via SUSVIMO ocular implant

What is the most important information I should know about SUSVIMO? SUSVIMO (ranibizumab injection) is delivered into the eye using the SUSVIMO implant. The SUSVIMO implant and the procedures to insert, fill, refill and remove the eye (ocular) implant can cause serious side effects including:

- an eye infection (endophthalmitis). Endophthalmitis is an infection of the eyeball that can cause permanent damage to your eye including blindness. Call your healthcare provider right away if you have increasing eye pain, vision loss, sensitivity to light, or redness in the white of the eye. Endophthalmitis requires urgent (same day) medical or surgical treatment.
- a missing layer on top of the white part of the eye (conjunctival erosion). Conjunctival erosion is an area that becomes missing (defect) in the layer (conjunctiva) that covers the white part of the eye which may result in exposure of the implant. Call your healthcare provider right away if you have a sudden feeling that something is in your eye, if you have eye discharge, or watering of the eye. Conjunctival erosion may require surgical treatment.
- an opening of the layer that covers the white part of the eye (conjunctival retraction). Conjunctival retraction is an opening or gaping in the layer (conjunctiva) that covers the white part of the eye which may cause the implant to be exposed. Call your healthcare provider right away if you have a sudden feeling that something is in your eye, if you have eye discharge, or watering of the eye. Conjunctival retraction may require surgical treatment.

See "What are the possible side effects of SUSVIMO?" for other serious side effects that may happen while in treatment with SUSVIMO.

To help prevent or keep these side effects from becoming more serious follow all post-procedure instructions your healthcare provider gives you. See "How will I receive SUSVIMO?".

#### What is SUSVIMO?

SUSVIMO (ranibizumab injection) is a prescription medicine used to treat adults with:

- Neovascular (wet) Age-related Macular Degeneration (AMD) who have responded to at least two injections of a Vascular Endothelial Growth Factor (VEGF) inhibitor in the gel-like part of the eye (intravitreal).
- Diabetic Macular Edema (DME) who have responded to at least two injections of a Vascular Endothelial Growth Factor (VEGF) inhibitor in the gel-like part of the eye (intravitreal).

It is not known if SUSVIMO is safe and effective in children.

#### Do not receive SUSVIMO if you:

- have an infection in or around your eye.
- have active swelling around your eye that may include pain and redness.
- are allergic to ranibizumab or any of the ingredients in SUSVIMO. See the end of this Medication Guide for a complete list of ingredients in SUSVIMO.

Talk to your healthcare provider before receiving this SUSVIMO if you have any of these conditions.

## Before receiving SUSVIMO, tell your healthcare provider about all of your medical conditions, including if you:

- are currently taking or have recently taken medicines that lower the chance of blood clots forming in the body such as warfarin, low or regular doses of aspirin, or nonsteroidal anti-inflammatory drugs (NSAID).
- are pregnant or plan to become pregnant. It is not known if SUSVIMO will harm your unborn baby. You should use birth control during your treatment with SUSVIMO and for 12 months after your last dose of SUSVIMO.
- are breastfeeding or plan to breastfeed. It is not known if SUSVIMO passes into your breast milk. Talk to your healthcare provider about the best way to feed your baby if you receive SUSVIMO.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

#### How will I receive SUSVIMO?

- SUSVIMO is implanted through the white part of the eye (sclera) by your healthcare provider.
- Your healthcare provider will refill your implant device every 6 months (about every 24 weeks) if you have AMD or DME.
- If you miss a scheduled refill, call your healthcare provider as soon as possible to reschedule your refill. Your next refill should be given 6 months after your last refill.

Your healthcare provider will give you instructions to follow after the implant insertion, the refill procedure, and the implant removal. The instructions may include:

#### After the Implant Insertion:

#### • Positioning of your head

- Keep your head above shoulder level for the rest of the day.
- Sleep with your head on 3 or more pillows during the day and night after your implant insertion.

#### • How to care for your eye

- **Do not** remove the eye shield from your eye until you are told to by your healthcare provider. At bedtime, continue to wear an eye shield for **at least 7 nights** following the implant insertion.
- Take all post-operative eye medicines as your healthcare provider tells you to.
- Do not push on the eye, rub the eye, or touch the area of the eye where the implant is located (underneath the eyelid in the upper and outer part of your eye) for 30 days following the implant insertion.
- **Do not** participate in strenuous activities until 1 month after the implant insertion or after talking to your healthcare provider.

#### • Magnetic Resonance Imaging (MRI) Implant Card

- Get your implant card from your healthcare provider after receiving the implant and keep the card in a safe place for future reference. The implant card contains important information about your SUSVIMO implant.
- Show your current and future healthcare providers your implant card. This is important if you need to have an MRI. You may only receive an MRI under very specific conditions if you have the SUSVIMO implant. Your healthcare provider will review the information on the implant card and will let you know if you should receive an MRI.

#### After the Refill Procedure:

- **Do not** push on the eye, rub the eye, or touch the area of the eye where the implant is located (underneath the eyelid in the upper and outer part of your eye) for **7 days** following the refill procedure.
- Take eye drops exactly as your healthcare provider tells you to take them.

#### After the Implant Removal:

- Keep your head above shoulder level for the rest of the day.
- Sleep with your head on 3 or more pillows if lying down during the day and night after implant removal.
- Wear an eye shield for at least 7 nights following the implant removal.
- Do not participate in strenuous activities until **14 days** following the implant removal.
- o Give all post-operative drops, as told by your healthcare provider.

These are not all the instructions you may receive from your healthcare provider. Following all post-procedure instructions may help prevent serious side effects or keep side effects from becoming more serious. See **"What is the most important information I should know about SUSVIMO?"**.

#### What should I avoid while receiving SUSVIMO?

- **Do not** drive or use machinery until the eye shield can be removed and you can see.
- Avoid rubbing your eye or touching the area of your eye where the implant is located as much as possible while the implant is in place. If you have to rub or touch your eye, wash your hands first.

#### What are the possible side effects of SUSVIMO?

See "What is the most important information I should know about SUSVIMO?" on the first page.

In addition to those side effects listed on page one, the SUSVIMO implant and the procedures to insert, fill, refill and remove the eye (ocular) implant can cause other serious side effects including:

- Tear and separation of layers of the retina (Rhegmatogenous retinal detachment). Rhegmatogenous retinal detachment is a tear and separation of one of the layers of the retina in the back of the eye that senses light. Call your healthcare provider or go to the emergency room right away if you see flashing lights, see a curtain or veil covering part of your vision, have a change in your vision, or a loss of vision. Rhegmatogenous retinal detachment requires surgical treatment.
- **Implant movement (Implant dislocation):** Tell your healthcare provider right away if you notice that the implant has moved out of place. This movement may require surgical treatment to correct.
- **Implant damage**: Damage to the implant that prevents continued treatment (refills) with SUSVIMO. If the implant is not able to be properly refilled, your wet AMD may be inadequately treated and your physician may remove the implant and/or change your treatment.
- Bleeding (Vitreous hemorrhage): Vitreous hemorrhage is bleeding within the gel-like substance (vitreous) inside of your eye. Call your healthcare provider right away if you have an increase in moving spots or what looks like spider webs in your vision as you may need an additional eye surgery.
- Bump on top of the white layer of the eye (Conjunctival bleb): Conjunctival bleb is a small bulge in the layer (conjunctiva) that covers the white part of the eye where the implant is inserted. This may be due to leakage of fluid from the inside of the eye. Call your healthcare provider right away if you have a sudden feeling that something is in your eye (foreign body sensation), see a bulge over the white part of your eye, if you have eye discharge, or watering in the eye. You may need medical or surgical treatment.
- Temporary decrease in vision after the SUSVIMO procedure.

The most common side effects of SUSVIMO include:

- blood on the white of the eye
- eye pain

- redness in the white of the eye
- sensitivity to light

These are not all the possible side effects of SUSVIMO.

Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

You may also report side effects to Genentech at 1-888-835-2555.

General information about the safe and effective use of SUSVIMO.

Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. You can ask your pharmacist or healthcare provider for information about SUSVIMO that is written for health professionals.

What are the ingredients in SUSVIMO (ranibizumab injection)?

Active ingredient: ranibizumab

Inactive ingredients: histidine HCI, polysorbate 20, sucrose.

Manufactured by: **Genentech, Inc.**, A Member of the Roche Group, 1 DNA Way, South San Francisco, CA 94080-4990 U.S. License No.: 1048

This Medication Guide has been approved by the U.S. Food and Drug Administration

Revised: 2/2025